Molecular modeling and SAR studies of CDK5/p25 selective inhibitors by Chatterjee, Arindam
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
1-1-2013 
Molecular modeling and SAR studies of CDK5/p25 selective 
inhibitors 
Arindam Chatterjee 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Chatterjee, Arindam, "Molecular modeling and SAR studies of CDK5/p25 selective inhibitors" (2013). 
Electronic Theses and Dissertations. 1452. 
https://egrove.olemiss.edu/etd/1452 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
  
MOLECULAR MODELING AND SAR STUDIES OF CDK5/p25 SELECTIVE INHIBITORS 
 
 
 
 
 
A Dissertation 
presented in partial fulfillment of requirements for the degree of  
Doctor of Philosophy 
in the Department of Medicinal Chemistry 
The University of Mississippi 
 
 
 
 
 
 
by 
ARINDAM CHATTERJEE 
November 2013 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright Arindam Chatterjee 2013 
 
ALL RIGHTS RESERVED 
 
ii 
 
ABSTRACT 
 Alzheimer’s disease (AD) is one of the most dreaded forms of progressive 
neurodegenerative diseases. The two main hallmarks of AD are the formation of amyloid senile 
plaques and neurofibrillary tangles. Cyclin dependent kinase 5 (CDK5) is a proline directed 
Serine/Threonine kinase, which expressed primarily in the central nervous system. In the 
biochemical process the CDK5-natural activator, p35 is cleaved by calpain to a shorter protein 
p25, which in turn hyperphosphorylates Tau, forms neurofibrillary tangles and causes AD. 
CDK5 deregulation is also indicated in other neurodegenerative diseases, such as Huntington’s 
chorea, stroke, Parkinson’s disease, amyotrophic lateral sclerosis, major depression and 
substance abuse.  
We chose to design CDK5/p25 inhibitors as a target against neurodegeneration leading to 
Alzheimer’s disease. One of our major goals was to design CDK5/p25 inhibitors selective over 
CDK2. Since we were targeting neurodegeneration we wanted to avoid any undesired cell cycle 
mediated apoptotic effects of CDK2 inhibition. The task was very challenging, because the two 
kinases possessed very high levels of sequence homology. In our approach we decided to 
achieve selectivity through structure based virtual screening strategy, validate the hits through 
biological screening and explore structure activity relationship (SAR) modifications around the 
lead structure.  
To identify de-novo templates, we decided to use the structure based E-pharmacophore 
models coupled with docking based virtual screening workflow to screen a commercially 
available database containing 2.84 million compounds. The biological screening was performed 
iii 
 
using radiometric filter binding assays with full length hCDK5/p25 and hCDK2/E kinases. An 
ATP non-competitive and selective inhibitor with ligand efficiency of 0.3 was identified as the 
lead molecule.  
We developed an efficient six-step synthesis of a key intermediate starting from aniline 
utilizing a sequence of Friedel-Crafts, Vilsmeier-Haack, nucleophilic aromatic substitution and 
cyclization reactions. We also developed an easy derivatization approach utilizing convergent 
analog synthesis to study SAR around the lead structure.   
Further SAR optimization led to the discovery of several low micromolar ATP non-
competitive CDK5/p25 inhibitors with much greater CDK2/E selectivity. This new series of 
compounds can be further evaluated in in-vitro and in-vivo AD models to develop future drug 
candidates. 
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CHAPTER 1: INTRODUCTION 
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1.1. Alzheimer’s disease  
 
Alzheimer’s disease (AD) is one of the most dreaded forms of progressive 
neurodegenerative diseases. According to a recent report, AD is the sixth leading cause of death 
in United States and is estimated to affect about 14 million individuals by the year 2050.
1
 The 
neuropathological hallmarks of AD were identified in 1906, when Dr Alois Alzheimer, a 
German physician, performed an autopsy on a cognitively impaired patient. The two main 
hallmarks leading to AD are the formation of amyloid senile plaques (SP) and neurofibrillary 
tangles (NFT).
2
 SPs are extra-cellular and mainly composed of -amyloid (A peptides, 
whereas intra-cellular NFTs are considered to be the downstream product of the hyper-
phosphorylated tau, a microtubule associated protein.
2, 3
  
The A peptides are formed by the proteolytic cleavage of the amyloid precursor protein 
(APP) by a complex enzymatic action involving -site amyloid precursor protein-cleaving 
enzyme 1 (BACE-1), a -secretase and -secretase. In general, an imbalance between the 
clearance and production causes A to accumulate and in the long run causes AD. On the other 
hand, the NFT formation occurs from taupathies.
4
 Tau is a phospho-protein, which involves 
mainly in neuronal tubulin polymerization and microtubule stabilization. Tau phosphorylation 
occurs during the normal process of neuronal development and is regulated by several protein 
kinases and phosphatases. But in taupathies, normal tau phosphorylation is deregulated, which 
leads to hyperphosphorylation. To date at least 85 tau phosphorylation sites has been described 
and a number of protein kinases are involved in these processes.
5
 Among them proline-directed 
kinases (PDPK), such as glycogen synthase kinase 3 (GSK-3), cyclin dependent kinase 5 (CDK 
5) and mitogen-activated protein kinases (MAPK) account for the phosphorylation of the 
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residues around the tubulin-binding region of the tau protein. Some other non-PDPK group of 
kinases, such as tau-tubulin kinases (TTBK), protein kinase A (PKA), protein kinase C (PKC), 
casein kinase (CK), microtubule affinity-regulated kinases (MARK) and calcium/calmodulin-
dependent protein kinases (CAMK) are involved in taupathies as well. 
Most normal adult neurons are post mitotic and don’t participate in cell cycle, while AD 
neurons re-enter the cell cycle but fail to complete mitosis and die. A recent theory hypothesizes 
neuronal cell cycle re-entry is the key step in the development of AD, which in turn produces A 
accumulation through tau.
6
  Some of the other popular theories include oxidative stress, 
mitochondrial dysfunction, disturbance in insulin-signaling pathway, vascular lesions, 
inflammation, elevated cytosolic calcium concentration, defective cholesterol metabolism etc. 
The currently available drugs, which can control the symptoms of cognitive impairment, are 
actylcholinesterase (ACh) inhibitors, such as aricept, exelon and razadyne. These drugs do not 
cure AD, but it improves the cognitive functions by increasing the ACh levels in the neurons.  
Currently there are several drugs undergoing clinical trials in AD patients, such as -secretase 
inhibitors, like semagacestat, avagacestat; -secretase inhibitor like LY2886721 and A 
immune-modulators like bapineuzumab and solanezumab. Unfortunately, these haven’t 
demonstrated any successes so far.  
One of the many mechanistic pathways leading to hyperphosphorylation of tau suggests 
the involvement of an atypical cyclin-dependent kinase (CDK), CDK5.
7-9
 We concentrated our 
focus on CDK5 inhibitors as a target for AD. 
1.2. Cyclin Dependent Kinase (CDK) 
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CDK5 is a proline-directed serine/threonine kinase (STK), belongs to a group of cyclin 
dependent kinase (CDK) family. To-date the CDK family consists of 20 CDKs (CDK1-20). 
CDKs are mainly involved in cell cycle process. The cell cycle of eukaryotic cells consist of four 
main successive phases: G1 phase (first gap), S phase (DNA synthesis), G2 phase (second gap) 
and M phase (mitosis) as described in Figure 1.1. 
 
 
Figure 1.1. Cell Cycle Process 
 
During G1, the activation of CDK4 and CDK6 with cyclin D, phosphorylates 
retinoblastoma protein (Rb), and inhibits the binding of transcription factor E2F-1. The E2F-1 is 
released and participates in the transcription in the next stages. In the late phase of G1, activation 
of CDK2/E ensures the G1/S transition. Throughout the S phase, CDK2/A phosphorylates 
various substrate to proliferate DNA replication. The DNA replication ends at the S phase, and 
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cells enter G2 phase, where CDK1/A regulates the phosphorylation of the substrates. The 
CDK1/B activation occurs at the late G2 phase and triggers the G2/M transition. The cyclin D 
reactivates the CDK4 and CDK6 to initiate the next cycle. In M phase the cells separate into two 
daughter cells.  
 Because of their involvements in the cell-cycle, the major focus of the drug development 
from CDKs was in the area of anti-tumor or anti-cancer. Representative examples of various 
CDK inhibitors currently in different phases of clinical trial are described in Figure 1.2. Even 
though they belong to CDK group, most of these inhibitors are classified as pan-kinase 
inhibitors, since they lack selectivity and inhibit other kinases. 
 
Figure 1.2. Representative CDK inhibitors in different phases of clinical trials 
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As discussed before, several evidences point towards the involvement of cell cycle 
kinases in neurodegenerative processes. These findings suggest that anti-tumor drugs with cell 
cycle inhibition may find its application in neuro-degeneration as well. Following are a few 
examples of CDK inhibitors being evaluated for neurodegeneration leading to AD (Figure 1.3). 
All of these compounds inhibit CDK5 and GSK3to some extents.  
 
 
Figure 1.3. CDK inhibitors evaluated for neurodegenerative diseases 
 
CDK5 is a unique member of the CDK family, which does not participate in cell division 
but it is important in neuronal tau phosphorylation leading to AD.  
1.3. Cyclin dependent kinase 5 (CDK5)  
 
Since the discovery of CDK5 in early 1990s, a lot of progress has been made in 
determining its functions. CDK5 is also known as neuronal CDC2-like kinase (NCLK). It is a   
proline-directed serine/threonine kinase (STK), which is primarily expressed in neuronal and 
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testicular cells. It is essential for the development of neuronal cells and is involved in the 
regulation of neuronal cytoskeleton dynamics; neurite outgrowth; vesicular transport and 
synaptic functions. The major difference of CDK5 with its other mitotic counterparts is that it 
regulates neuronal development rather than cell division.
10, 11
 The neuronal specificity is further 
established by the presence of its activators in the nervous system. It is primarily involved in 
neuronal migration, neuronal differentiation, synaptic functions and synapse development. 
Unlike other CDKs and STKs, it does not require ‘T-loop’ phosphorylation to achieve an active 
conformation.
10
 It is also involved in post mitotic neuronal survival, migration and 
neurogenesis.
12
 The post mitotic neuronal expression is marked by its activation by non-cyclin 
activators p35 and p39. However, it phosphorylates S/TPXK/R type motif as in other CDKs. 
Thus explains its inclusion in the CDK families.
13
 Phosphorylation at threonine 14 and serine 
159 produce inhibitory effects, whereas the activation is occurred by the phosphorylation at 
tyrosine 15.
14
 
Oxidative or ischemic neuronal damages increase neuronal calcium influx and thereby 
activate the cysteine-protease calpain. The membrane bound natural precursor p35 is then 
cleaved by activated calpain to a longer lived cytosolic protein p25, leading to the formation of a 
hyperactive p25/CDK5 complex.
14
 Such cleavage is reported as one of the key reasons for 
hyperphosphorylation of tau and subsequent NFT formation leading to AD.
7-9
 CDK5 
phosphorylates tau at 11 sites and all these phosphorylated sites exist in AD brain. CDK5 is also 
believed to be involved in the phosphorylation mediated activation of phosphatidylinositol-3-
kinase (PI3K)-like kinase ATM (ataxia-telangiectasia mutated). The activated ATM causes DNA 
damage-induced cell cycle re-entry and subsequent apoptosis.
12
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A recent study with CDK5 knockout transgenic mouse has shown direct reduction of the 
NFT formation.
15
 The in-vitro activity of CDK5/p25 inhibitors in Rat neuronal cells show dose-
dependent inhibition of tau phosphorylation.
16
  Inhibition of the p25-CDK5 complex is a viable 
target for AD, by blocking the hyperphosphorylation of tau and subsequent NFT formation. 
CDK5 deregulation is also indicated in other neurodegenerative diseases, such as Huntington’s 
chorea, stroke, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), major depression and 
substance abuse.
7, 17-19
 In non-neuronal systems it is indicated in the control of glucose 
metabolism in pancreatic beta cells
20
 and tumorigenesis of the pancreas.
21
 These therapeutic 
indications make it a very attractive target to investigate in depth. 
We chose to design CDK5/p25 inhibitors as a target against neurodegeneration leading to 
Alzheimer’s disease. One of our major goals was to design CDK5/p25 inhibitors selective over 
CDK2. Since we were targeting neurodegeneration we wanted to avoid any undesired cell cycle 
mediated apoptotic effects of CDK2 inhibition. The task is daunting, because the two kinases 
have about 60% sequence homology and commonality in the number of residues (27 out of 29) 
in the ATP binding domains. The only two differing amino acid residues in the catalytic domain 
for CDK5 are Cys83 and Asp84, whereas for CDK2 these are Leu83 and His84. Figure 1.4 
explains the 3-dimentional (3-D) difference in the catalytic domain of the two kinases.  
9 
 
 
Figure 1.4. 3-D difference in catalytic domains of CDK5 (blue) and CDK2 (brown) 
 
Even with these close sequential similarities some research groups have previously 
achieved the selectivity over CDK2 using homology model derived SAR studies. Three 
examples (1.1, 1.2 and 1.3) in Figure 1.5 have selectivity values of 18-, 34- and 99- fold, 
respectively.
22-24
  
 
10 
 
 
 
 
Figure 1.5. Structures of CDK5 selective compounds 
 In our approach we decided to achieve selectivity through structure based virtual 
screening strategy, validate the hits through biological screening and explore SAR modifications 
around the lead structure. 
. 
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CHAPTER 2: VIRTUAL SCREENING METHODOLOGY TO FIND SELECTIVE AND 
POTENT CDK5/p25 INHIBITORS 
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2.1  Introduction 
 
Inhibition of CDK5-p25 became a viable target for numerous acute and chronic 
neurodegenerative diseases; including Alzheimer disease. One of our major goals of designing 
selective CDK5/p25 inhibitors targeting neurodegeneration was to avoid any undesired mitotic 
side effects of CDK2. Even though R- roscovitine (2.1) had been explored as one of the kinase 
inhibitor for AD, it is not a selective CDK5/p25 inhibitor.
25
 The task of finding selectivity 
became daunting, because the two kinases have very high levels (60%) of sequence homology 
and commonality in the number of residues (27 out of 29) in the ATP binding domains. The only 
two differing amino acid residues in the catalytic domain for CDK5 are Cys83 and Asp84, 
whereas for CDK2 these are Leu83 and His84. 
Despite these similarities, the selectivity was achieved previously by different research 
groups, utilizing the ligand-based SAR strategies, where the lead compounds were identified by 
high throughput screening and were optimized by docking into homology models of CDK5/p25 
derived from the X-ray structures of CDK2.
23, 26, 27
 
The potential for structure-based inhibitor design received a shot in the arm with the 
availability of X-ray crystal structures of CDK5/p25.
10, 28, 29
 The first apo-protein structure 
deposited in the RCSB protein data bank (PDB) had a PDB id: 1H4L, which was in its active 
conformation and showed no phosphorylation in the T-loop (specifically at Ser159).
10
 Four other 
structures (PDB id: 3O0G, 1UNG, 1UNH and 1UNL)
29, 30
 have ligands embedded and all are 
crystallized from the mutant CDK5/p25 form in which Asp144 of the wild form was mutated 
with Asn144. Structures of the known ligands with available PDB id are described in Figure 2.1. 
13 
 
Even with the availability of the crystal structures, to-date only a few groups have utilized 
structure-based design using simple docking protocols to identify leads.
5, 16, 31
 
 
Figure 2.1. Structures of known CDK5/p25 inhibitors with PDB id 
 
Structure based virtual screening is a successful computational tool often used as 
complimentary to high throughput biological screening to identify hits.
32, 33
 In view of the 
potential therapeutic importance and available crystal structures (PDB id: 1UNG, 1UNH, 1UNL 
and 3O0G),
29, 30
 CDK5/p25 is an attractive target for structure based inhibitor design. However, 
no prospective virtual screening works have been reported to-date. A three dimensional 
quantitative structure-activity relationship (3D-QSAR) study
34
 has been reported aimed towards 
understanding the SAR requirements of previously disclosed CDK5/p25 inhibitors.
24
 Recently, a 
virtual screening effort
35
 reporting the validity of the docking model of previously known 
inhibitors fell short of disclosing any new structural cores. In this current research an in-silico 
approach was used to identify novel selective CDK5/p25 inhibitors using structure-based virtual 
14 
 
screening. Usually, structure-based virtual screening studies use either docking-based screening 
or pharmacophore matching.
32, 33
 To identify de-novo templates, we decided to use structure 
based E-pharmacophore models coupled with a docking-based virtual screening workflow to 
screen a commercially available database containing 2.84 million compounds with 4.28 million 
conformations. The computational approach can be divided into four distinct steps as described 
in the schematic representation (Figure 2.2).  
 
 
 
Figure 2.2. In-silico scheme for virtual screening study 
15 
 
In this approach we further imposed a selectivity ratio constraint and subsequently used 
clustering and similarity analysis to identify nine compounds. Among these nine compounds, one 
was identified as the lead with a 0.3 LE and four-fold selectivity over CDK2/cyclin E. 
 
2.2. Methods 
 
2.2.1. General 
 
All calculations were performed on a Linux workstation equipped with four parallel Intel 
Xenon X5460 processors (3.16 GHz) with 8GB total RAM. The pictures were generated using 
PyMol
36
 and Maestro, version 9.2.
37
  
2.2.2. Ligand Preparation 
 
LigPrep
38
 was used to produce low energy 3D structures of compounds. The 
ionization/tautomeric states were generated using Epik. The chiralities of the compounds were 
retained from the original state. All the conformations were minimized using OPLS-2005 force 
field and at the most 32 conformations per ligands were generated. 
2.2.3. Protein Preparation 
 
Each protein crystallographic structure was loaded from the RCSB Protein Data Bank 
(PDB) and prepared by using Protein Preparation Wizard.
39
 For the dimer, the ligand bound 
fragment was selected for processing. It was then pre-processed by assigning the bond orders, 
adding hydrogen, and filling in the missing loops and the side chains using Prime.
40
 The crystal 
16 
 
bound waters were deleted beyond 5Å from the ligand and ionization/tautomeric states were 
generated at pH 7.0±4.0 using Epik. Subsequently, the protein was refined by optimizing the 
hydrogen bonds (H bonds) and the sample water orientations. Finally the Impref-minimization 
was carried out using OPLS 2005 force field. 
2.2.4. Hypothesis generation 
 
The initial pharmacophoric hypotheses were generated from the PDB structures using E-
Pharmacophore.
41
 All the subsequent hypotheses were generated using Phase.
42, 43
  
2.2.5. Phase database generation  
 
A database was generated from known CDK5/p25 inhibitors,
27, 29, 30, 44-59
 using Phase.
60
 
The ligand conformations were generated by Phase ligand processing using the following 
protocol. Different ionization/tautomeric states were generated at pH 7.0±2.0 using Epik and the 
high-energy states were removed. The stereochemical information was obtained from the 3D 
geometry of the ligands. For unspecified stereocenters, 4 low-energy stereo isomers were 
retained. For 5/6 membered rings the default value of up to 1 conformation per structure was 
retained. Duplicate structures were skipped. A default value of maximum number of 100 
conformers was generated per molecule and up to 10 conformations were retained per rotatable 
bond. 
2.2.6. Phase Database Screening   
 
 Both the Phase databases (the database built from known CDK5/p25 inhibitors and the 
commercial database) were screened to find pharmacophore matches
42, 43
 using existing 
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conformers. For the database build from the known CDK5 inhibitors, the return limit was set as 
at most 1 hit per molecule and 1000 hits in total. On the other hand, for the commercial database 
the limit was set as, at most 1 hit per molecule and 10,000 hits in total. In both the cases, the hits 
with align scores >1.2, vector scores <-1.0 and volume scores <0.0 were rejected. 
2.2.7. Ligand docking 
 
 All the docking calculations were performed with (extra precision) XP-Glide, because it 
was known to be more accurate and computationally intensive
61, 62
 and run in the Virtual 
Screening Workflow framework. The ligands were pre-processed using LigPrep. Docking grids 
were generated by Glide using the co-crystallized ligand at the center of the grid box. The 
compounds were docked flexibly by using penalization for non-planar amide bond 
conformations and after docking 100% of the best compounds with all good scoring states were 
kept.  
2.2.8. Fingerprinting, Similarity and Clustering Analysis 
 
 We performed the analysis of the virtual screening hits first by creating fingerprints using 
Radial fingerprinting.
63
 Then the similarity analysis of the fingerprints was done using Tanimoto 
similarity
64
 and hierarchical clustering by Ward’s cluster linkage method65 in Canvas.66 
 
2.3. Results and Discussion 
 
2.3.1. Protein selection and evaluation of waters in crystal structures 
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Several previous computational studies have explored the importance of water molecules 
in the active site domains of proteins and showed that they were pivotal for ligand binding in 
virtual-screening frameworks.
67, 68
 We first explored the significance of the water molecules in 
the crystal structures of CDK5/p25 (PDB id: 3O0G, 1UNL, 1UNG and 1UNH).
28, 29
 In the 
protein preparation methodology we first considered keeping the highly conserved water 
molecules within 5Å of ligand binding distances. We also prepared the proteins without any 
water. Subsequently, the co-crystallized ligands were docked using Glide -XP to both the water-
bound and the water-removed forms of the individual proteins. We observed that for all four 
cases the ligands showed better GlideScores with the water-bound forms (Table 2.1). This 
prompted us to prepare all proteins (both CDK5/p25 and CDK2) with conserved waters in the 
5Å of their ligand binding domain.  
 
Table 2.1.  XP-docking scores of ligands in water bound and no-water-bound proteins 
 
 
 
 
 
 
 
In the ensemble-docking experiment of the CDK5/p25 crystal bound ligands we found 
that only co-crystallized ligands produced good GlideScores with the originating proteins (Table 
2.2).  
CDK5/p25 Protein 
Structures 
Status of water in 
crystal structure 
GlideScores 
3O0G 
water bound -10.570 
no water -9.925 
1UNL 
water bound -9.968 
no water -9.554 
1UNG 
water bound -9.208 
no water -8.419 
1UNH 
water bound -8.263 
no water -7.441 
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This made us believe that no single protein structure could be used to dock all the ligands 
and consequently we chose all four CDK5/p25 crystal structures for the virtual screening study.  
 
Table 2.2.  Ensemble docking of CDK5/p25 crystal bound ligands  
Protein PDB 
id 
Crystal bound 
Ligands 
GlideScores 
3O0G 
Ligand_3O0G -10.570 
Ligand_1UNH -8.542 
Ligand_1UNG -8.401 
Ligand_1UNL -5.530 
1UNL 
Ligand_1UNL -9.968 
Ligand_1UNG -8.498 
Ligand_3O0G -8.325 
Ligand_1UNH -7.678 
1UNG 
Ligand_1UNG -9.208 
Ligand_1UNH -6.737 
Ligand_1UNL -4.612 
Ligand_3O0G -3.912 
1UNH 
Ligand_1UNH -8.263 
Ligand_3O0G -6.594 
Ligand_1UNL -5.999 
Ligand_1UNG -5.883 
 
 
With respect to CDK2, since 148 structures with a resolution of ≤ 2.5Å were available in 
the PDB between 1996-2011, we had to narrow down our selection through similarity 
searching,
64
 followed by hierarchical clustering
65
 to six structures (PDB id: 1AQ1, 2W17, 1OIT, 
2A4L, 2VTP and 1R78).
69-74
 While analyzing the data from ensemble-docking study of these six 
co-crystallized ligands, we found that all ligands docked reasonably well with 2VTP only (Table 
2.3). Consequently, 2VTP was chosen as the CDK2 protein for the virtual screening work-flow. 
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Table 2.3.  Ensemble docking of CDK2 crystal bound ligands 
Protein 
Structures 
Crystal bound 
Ligands 
GlideScores 
1AQ1 
Ligand_1AQ1 -13.324 
Ligand_2VTP -10.099 
Ligand_1OIT -9.906 
Ligand_1R78 -8.256 
Ligand_2A4L -8.117 
Ligand_2W17 -4.511 
2W17 
Ligand_2W17 -11.763 
Ligand_1OIT -11.185 
Ligand_2A4L -10.681 
Ligand_2VTP -8.965 
Ligand_1R78 -6.146 
Ligand_1AQ1 -1.955 
1OIT 
Ligand_1OIT -11.324 
Ligand_2W17 -10.102 
Ligand_1R78 -9.914 
Ligand_2VTP -8.477 
Ligand_2A4L -6.960 
Ligand_1AQ1 * 
2A4L 
Ligand_2W17 -10.450 
Ligand_1R78 -9.762 
Ligand_2A4L -9.592 
Ligand_1OIT -7.258 
Ligand_2VTP -5.645 
Ligand_1AQ1 -3.240 
2VTP 
Ligand_1OIT -11.279 
Ligand_2VTP -10.470 
Ligand_2W17 -9.874 
Ligand_1R78 -9.102 
Ligand_2A4L -7.590 
Ligand_1AQ1 -7.434 
1R78 
Ligand_2W17 -10.488 
Ligand_2A4L -9.256 
Ligand_1OIT -8.886 
Ligand_1R78 -8.724 
Ligand_2VTP -8.418 
Ligand_1AQ1 -5.067 
* Ligand did not dock in the selected grid 
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2.3.2. Primary screening and validation 
 
For a rapid screening of a large database, we extracted the pharmacophoric features 
required for CDK5/p25 inhibition from the known x-ray structures (PDB id: 1UNL, 1UNH, 
1UNG, 3O0G)
28, 29
 and derived E-pharmacophore models
41, 75
 using Maestro.
37
 The structure-
based pharmacophore model generated from 1UNL contained seven features: two hydrogen 
bond acceptors (A2, A4, red spheres), two hydrogen bond donors (D5, D6, blue spheres), one 
hydrophobic feature (H8, green sphere) and two ring aromatics (R11, R12, red rings) (Figure 2.3, 
generated by Maestro.
37
). Similar pharmacophore models were generated from 1UNH as 
A3D4H8R10; from 1UNG as A1A2D5H6R8R9; and from 3O0G as A1A2D3D4R7R8 (Figure 
2.3). 
 
 
Figure 2.3.  E-pharmacophoric features of 1UNG, 1UNH, 1UNL and 3O0G  
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In these e-pharmacophore models, some of the generated features did not comply with 
the original hydrogen bonding (H-boding) interactions of the ligands. The H-bonding 
interactions are shown in Figure 2.4 and the interaction diagrams were generated in the RCSB 
PDB by PoseView.
76-78
 Considering these interactions we created a total of twelve hypotheses: 
five from the E-pharmacophore model of 1UNL, two from 1UNH, three from 1UNG and two 
from 3O0G (Table 2.4). The next goal was to validate and select a concise list from these twelve 
hypotheses for virtual screening study.  
 
 
Figure 2.4. H-bonding interaction diagrams of 1UNH, 1UNL, 3O0G and 1UNG 
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Table 2.4. Hypotheses generated from E-pharmacophores 
E-pharmacophore Hypotheses Pharmacophoric features 
1UNG 
1UNG_hypo 1 A1A2D5H6R8R9 
1UNG_hypo 2 A1A2D5R8R9 
1UNG_hypo 3 A2D5R8R9 
1UNH 
1UNH_hypo 1 A3D4H8R10 
1UNH_hypo 2 A1A3D4H8R10 
1UNL 
1UNL_hypo 1 A2D5D6R11R12 
1UNL_hypo 2 A2D6H8R11R12 
1UNL_hypo 3 A2A4H8D6R11R12 
1UNL_hypo 4 A2D5D6H8R11R12 
1UNL_hypo 5 A2A4D5D6H8R11R12 
3O0G 
3O0G_hypo 1 A1A2D3D4R7R8R9 
3O0G_hypo 2 A1A2D3D4R7R8 
 
The validations of the hypotheses were done in two steps, first by Phase
60
 screening of an 
in-house database containing known CDK5/p25 inhibitors,
27, 29, 30, 44-59
  followed by Glide 
docking
61
 of these screened hits in a CDK2 crystal structure (PDB id: 2VTP) using XP 
docking.
62
 Number of compounds in each hypothesis with relatively poor GlideScores (≥ -5.0) in 
CDK2 and good experimental activity (IC50 ≤ 0.6 M) in CDK5/p25 were identified (Figure 
2.5).  
 
 
Figure 2.5.  Number of hits in each hypothesis  
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On the basis of their rank order, one hypothesis from each of 1UNH, 1UNG and 3O0G 
and three from 1UNL were selected, as described in Table 2.5.  
 
Table 2.5. Validated Hypotheses 
Selected Hypotheses Pharmacophoric Features 
1UNG-hypo 3 A2D5R8R9 
1UNH-hypo 1 A3D4H8R10 
1UNL-hypo 1 A2D5D6R11R12 
1UNL-hypo 2 A2D6H8R11R12 
1UNL-hypo 3 A2A4H8D6R11R12 
3O0G-hypo 2 A1A2D3D4R7R8 
 
2.3.3. Structure-based virtual screening 
 
In our virtual screening study we used a commercial database
79
 containing 2.84 million 
compounds with 4.28 million conformations. We did not perform any further refinements of the 
database since the conformations were generated using ligprep,
38
 Phase
60
 and ADME property 
screens.
80
 
As an initial step, we decided to use Phase based quick pharmacophore match
43
 for the 
top six hypotheses as an alternative to the computationally exhaustive docking based virtual 
screening work-flow.  
Subsequently, these six sets of hits were docked separately in CDK2 crystal structure 
(PDB id: 2VTP) using XP Glide.
61
 In several previous studies, GlideScores had been used as a 
predictive tool to rank score compounds in virtual screening.
62, 81
 We incorporated this predictive 
methodology in our scheme. We selected a cut-off CDK2 GlideScores ≥ -6.0 as a benchmark for 
compounds to be less active in CDK2. With this threshold in place we selected a total of 21,284 
potential poor-CDK2-active compounds. 
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Compounds identified with the poor CDK2 GlideScores were docked into CDK5/p25 
crystal structures (PDB id: 1UNL, 1UNH, 1UNG, 3O0G) using XP Glide. The set of compounds 
identified from the initial Phase screening of 1UNG-hypotheses, docked in 1UNG. The 
compounds identified from the other three protein-generated hypotheses were docked similarly. 
We used a cut-off GlideScores ≤ -7.5 to identify compounds as potential CDK5/p25 active 
compounds. Consequently, we identified 1741 potential CDK5/p25 selective compounds with 
poor CDK2 GlideScores (≥ -6.0) and good CDK5/p25 GlideScores (≤ -7.5). We further refined 
the selection of compounds by imposing a selectivity constraint (≥ 1.5) as defined below: 
Selectivity Constraint =  
CDK5/p25 GlideScores
 CDK2 GlideScores
  ≥ 1.5 
In total we identified 884 computationally defined active CDK5/p25 compounds with 
selectivity against CDK2. 
2.3.4. Selection of compounds 
 
The selected 884 compounds were statistically analyzed using 2-dimesional (2-D) Radial 
fingerprinting,
63
 in Canvas.
66
 The hierarchical clustering of the fingerprints identified 49 diverse 
sets of clusters using Tanimoto similarity and Ward’s cluster linkage method.65 We eventually 
identified 62 compounds from these 49 diverse sets, which were further optimized through a 
second round of 2-D fingerprinting and clustering to a group of 17 compounds. Final selection of 
9 compounds was done by knowledge-based screening. These selected nine compounds along 
with the carboxylic acid intermediate 3.14 are represented in Figure 2.6. 
Commercial or in-house sources, docking scores and calculated properties of the 
compounds are listed in Table 2.6. Physicochemical and ADME properties, such as logP 
(octanol/water), logBB (log [brain]/[blood] (a predictor of a compound’s ability to cross blood-
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brain barrier) and number of metabolic sites (# metab) calculated by QikProp
80
 are listed. The 
values of intermediate carboxylic acid (2.14) were also calculated and included in Table 2.6. The 
log BB for a good oral CNS drug usually is between -3.0 to 1.0. All the selected compounds 
showed good predicted blood-brain barrier (BBB) permeability. 
 
 
Figure 2.6. Selection of compounds from virtual screening study 
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Table 2.6. Calculated properties and sources of compounds selected in virtual screening 
 
 
2.4 Conclusions 
 
A virtual screening work-flow comprised of pharmacophore matching, docking based 
screening methodology and constraint-based filtration was used to identify nine compounds from 
a commercial data-base containing 2.84 million compounds with 4.28 million conformers. This 
unique combination of e-pharmacophore matching and structure-based virtual screening was 
used to identify compounds with de-novo structural class. All the nine compounds showed 
excellent in-silico predicted blood-brain permeability. Along with these nine compounds the 
carboxylic acid intermediate (2.14) was also evaluated in in-vitro CDK5/p25 and CDK2/E kinase 
assays to find the validity of the model. The success rate of the model was defined by finding 
compounds with activity in CDK5/p25 and selectivity over CDK2/E. We found a 40% success 
Compound 
# 
CDK5/ p25 
Glide Score 
CDK2 Glide 
Score 
Sources MW  
LogP 
(o/w) 
LogBB 
# 
Metab 
2.5 -7.827 -3.673 
Synthesized in-
house 
295.72 2.066 -0.823 2 
2.6 -8.201 -4.069 Chem Bridge 415.90 4.071 -1.193 3 
2.7 -9.221 -4.775 Ryan Sci. 412.53 3.685 -1.664 5 
2.8 -7.582 -3.973 Ryan Sci. 334.39 1.233 -1.767 2 
2.9 -8.007 -4.332 Chem Div 437.47 2.557 -2.107 6 
2.10 -9.469 -5.539 
Synthesized in-
house 
335.38 2.548 -1.020 4 
2.11 -8.612 -5.240 Chem Bridge 308.37 4.134 -1.023 5 
2.12 -8.908 -5.570 Ryan Sci. 312.33 1.522 -1.329 5 
2.13 -7.864 -5.065 Chem Div 374.44 3.802 -1.115 3 
2.14 -9.730 -8.117 
Synthesized in-
house 
245.25 1.418 -1.027 2 
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rate for the computational model with the identification of a lead with ligand efficiency (LE) of 
0.3, as discussed in Chapter 6. 
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CHAPTER 3: SYNTHESIS OF STANDARDS AND 4-OXO-4,5 DIHYDROTHIENO[3,2-
c]QUINOLINE-2-CARBOXYLIC ACID DERIVATIVES 
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3.1. Introduction 
  
 Because of high costs and long turn-around times, our initial focus was to prepare the 
2,4-diaminothiazole standard (2.4) and the virtual screening hits (2.5 and 2.10). After the initial 
in-vitro assay of the identified hits from the virtual screening effort, we identified a lead 
molecule (2.10) in our effort with a ligand efficiency of 0.3. Consequently our effort in 
developing future SAR compounds around the lead also prompted us to develop an easy 
convergent synthesis. 
We have noticed that in a previously reported method, synthesis of the 2,4- 
diaminothiazole derivative (2.4) was accomplished in two steps (Scheme 3.1).
16
  
 
 
Scheme 3.1. Known synthesis of 2.4 
 
Reagents and conditions: (i) DIPEA or KOH, DMF, 50 °C, 2-16 h; (ii) DIPEA or TEA, DMF, 
50-70 °C, 2-16 h 
 
 
We observed that although the structures 2.5 and 2.10 were listed in SciFinder
®
, 
82
 there 
was no associated references. This motivated us to develop new and straight-forward strategies 
for the syntheses of the compounds. For synthesizing 2.10, we searched for its closest 
intermediate, 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14). We found that 
the intermediate carboxylic acid (2.14) was also listed in SciFinder
®
 
82
 without any associated 
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references. This led us to develop a synthesis for the versatile intermediate 2.14 and rapid 
convergent synthesis of its derivatives for future SAR development.  
 
Figure 3.1. Structure of the thieno[3,2-c]quinolin-4(5H)-one (3.1)  
 
Several groups have explored the synthesis of the core structure (3.1) through free radical 
chemistry or transition metal mediated synthesis with varied yields ranging from 13-86% 
83-86
. 
These palladium or copper mediated transition metal syntheses or the free radical chemistry are 
often hard to scale-up and pose issues relating purification and overall cost (Scheme 3.2). Only a 
few reports exist so far for the synthesis of the C-ring substituted derivatives of 3.1 (Scheme 
3.2). Pierre et al. utilized palladium mediated cross coupling reaction and subsequent 
bromination to synthesize the 2-bromo derivative of 3.1 in very low yield. 
85, 87
 A ring expansion 
Beckmann rearrangement was used in a multi-step synthesis of 2-phenyl substituted derivatives 
of 3.1 in moderate yield 
88
 (Scheme 3.2). Efforts have also been made to synthesize N-alkylated 
derivatives of 2.14 
89-91
. However, difficulty in synthesizing the unstable -chloro aldehyde (3.2) 
and subsequent cyclization barred any known synthesis available for C-ring substituted 
thienoquinolone moiety with free NH- lactam (2.14).  
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Scheme 3.2. Known syntheses of core structure (3.1) and derivatives 
 
Reagents and conditions: (i) AIBN, 1,10-phenanthroline, KOtBu, benzene, 110 °C, 2-16 h; (ii) 
Pd(PPh3)4, Na2CO3, 1,2-dimethoxyethane, 120 °C, 5 h; (iii) Fe, AcOH, THF, 6 h; (iv) NaOAc, 
PdCl2(dppf), DMF, mw, 120 °C, 10 min; (v) CHCl3, AcOH, NBS, 70 °C, 16 h; (vi) NaOEt, 
EtOH, 100 °C, 30 min; (vii) Lawesson’s reagent, toluene, 110 °C, 6 h; (viii) NH2OH, NaOAc, 
120 °C, 4 h; (ix) P2O5, H3PO4, 80-100 °C, 3 h. 
 
Our proposed scheme starts with aniline (3.4) and utilizes a sequence of Friedel-Crafts, 
Vilsmeier-Haack, nucleophilic aromatic substitution (SNAr) and cyclization reactions to achieve 
the synthesis of the target compound (2.14). The retro-synthetic approach is described in Scheme 
3.3.   
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Scheme 3.3. Retro-synthetic approach for the synthesis of 2.14 
 
3.2. Results and Discussions 
We developed an efficient one-pot condensation of (4-amino-2-((4-
chlorophenyl)amino)thiazol-5-yl)(3-nitrophenyl) methanone (2.4). (Scheme 3.4) from 
cyanamide, a substituted phenyl isothiocyanate (3.5) and a -halo acetophenone derivative 
(3.6).
92
  
 
Scheme 3.4. One-pot synthesis of 2,4-diaminothiazole derivative (2.4)  
 
Reagents and conditions: (i) Cyanamide, KOtBu, ACN, t-BuOH, 30 °C, 2 h, 59%. 
 
The synthesis of 2-((4-((4-chlorophenyl)amino)-6-methoxy-1,3,5-triazin-2-
yl)amino)ethanol (2.5) was effectively achieved from 2,4-dichloro-6-methoxy-1,3,5-triazine 
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(3.7) by successive nucleophilic aromatic substitutions (SNAr) with 4-chloroaniline and 
ethanolamine in one-pot (Scheme 3.5).
93
  
 
 
Scheme 3.5.  One-pot synthesis of triazine derivative (2.5)  
 
Reagents and conditions: (i) 4-Chloroaniline, iPr2NEt, DCM, 30 °C, 15 min; (ii) Ethanolamine, 
30 °C, 5 h, 70% 
 
In our synthetic approach for 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid 
(2.14), we first synthesized 4-hydroxyquinolin-2(1H)-one (3.3) starting from anthranilic acid 
(3.8) in three steps (Scheme 3.6).
94
 
  
Scheme 3.6. Initial synthesis of 4-hydroxyquinolin-2(1H)-one (3.3) 
 
Reagents and conditions: (i) MeOH, conc. H2SO4, 70 °C, 12h, 64%; (ii) Acetic anhydride, 
dioxane, 80 °C, 2h, 56%; (iii) KN(SiMe3)2, THF, -78 ° to 25 °C in 12h, 40%. 
 
In order to optimize the yield we tried an alternate synthesis for 3.3. We first attempted a 
direct microwave conversion of aniline (3.4) and diethylmalonate to 4-hydroxyquinolin-2(1H)-
one (3.3.) 
95, 96
. Contrary to the reported findings, we could never repeat the direct synthesis of 4-
hydroxyquinolin-2(1H)-one (3.3) as reported in the literature.
95, 96
 Instead N
1
,N
3
-
diphenylmalonamide (3.8) was obtained exclusively in 60% yield (Scheme 3.5). We optimized 
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the procedure by using a varied mix of aniline and diethylmalonate with catalytic amount of 
DMF in microwave and conventional heating as described in Table 3.1.  
 
Table 3.1. Optimization of the conversion of 3.4 to 3.8 
Entry Aniline 
Diethyl 
malonate 
Heating 
condition 
Time 
Temperature 
(°C) 
Isolated 
yield (%) 
1 1 eq 1 eq microwave 1h 80 34 
2 2 eq 1 eq microwave 1h 80 48 
3 1 eq 1 eq conventional 8h 80 34 
4 2 eq 1 eq conventional 8h 80 95 
 
The optimum condition was the use of a (2:1) mixture of aniline and diethylmalonate 
with a catalytic amount of DMF at 140 °C for 8h to get 6 as a white solid in 95% yield. The 
structure of 3.11 was confirmed by comparing the 
1
H NMR and melting point (mp) with the 
known literature values 
97
. Finally, 4-Hydroxyquinolin-2(1H)-one (3.3) was obtained by intra 
molecular Friedel-Crafts acylation of 3.11 by heating it with polyphosphoric acid (PPA) at 150 
°C for 3h 
98
. Chromatographic purification was avoided by a simple acid-base workup, resulting 
in pure 3.3 in 74% yield. This alternate method improved the yield of 3.3 and reduced the 
number of steps used in Scheme 3.6. The improved synthesis is described in Scheme 3.7. 
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Scheme 3.7. A two-step synthesis of 3.3  
 
Reagents and conditions: (i) Diethyl malonate, cat. DMF, mw, 135 °C, 30 min; (ii) 
Diethylmalonate, cat. DMF, 140 °C, 8 h, 95%; (iii) PPA, 150 °C, 3 h, 70%. 
 
 Our attempt to convert 3.3 directly to the -chloro aldehyde (3.2) failed to yield the 
desired product 
99
. However, we were able to convert 3.3 to an intermediate azomethine 
containing 3-((phenylamino)methylene)quinoline-2,4(1H,3H)-dione (3.12), which was easily 
converted to the -chloro aldehyde (3.3) by a Vilsmeier-Haack reaction 100 (Scheme 3.8).  
 
 
Scheme 3.8. Synthesis of -chloro aldehyde, 3.3 -via- azomethine intermediate 
 
Reagents and conditions: (i) POCl3, DMF, 8h, no reaction; (ii) POCl3, DMF, 8h, 90%; (iii) 
triethyl orthoformate, ethylene glycol, mw, 145 °C, 20 min, 82%. 
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While characterizing 3.12, we noticed a striking difference between the reported 
1
H-
NMR chemical shifts 
100
 and our observed data. We observed two new chemical shifts at 13.70 
(d, J = 12.5 Hz) and 12.81 (d, J = 12.5 Hz) ppm, which collectively integrated as one proton. We 
speculated that 3.12 exists as both the (E)- and (Z)- isomers as depicted in Figure 3.2, which 
were not reported either by Chilin et al. 
100
 or Fiala et al. 
101
. 
  
 
Figure 3.2. (E) and (Z) isomers of 3.12 
 
In order to confirm our speculation, we first assigned the chemical shifts (in ppm) of A, 
B, C and D at 25 °C (Fig. 3.3), as follows. Three signals at 10.89 – 10.84 (m, 1H), 13.70 (d, J = 
12.5 Hz) and 12.81 (d, J = 12.5 Hz) were exchanged by D2O wash, confirming as -NH signals. 
By comparing the spectrum of 3.3, the signal at 10.89-10.84 (m) was assigned to the lactam -NH. 
The doublet at 8.88 was assigned for H-C11, from COSY (see in appendices), which showed 
correlation of the peak only with the two exchangeable signals at 13.70 and 12.81. In summary, 
signal D at 8.88 (d, J = 12.0 Hz, 1H, H-C11), signal C at 10.89 – 10.84 (m, 1H, H-N1), signal B at 
13.70 (d, J = 12.5 Hz, H-N12) and signal A at 12.81 (d, J = 12.5 Hz, H-N12) were assigned. Since 
COSY showed correlations of D (H-C11) with both A (H-N12) and B (H-N12), we wanted to 
investigate further to confirm whether 3.12 is a mixture of tautomers or two geometric isomers 
(E- and Z-).  
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Figure 3.3.  VTE of the azomethine intermediate 3.12 
 
We designed a variable temperature NMR experiment (VTE) from 25 °C to 80 °C and it 
was observed that each signal individually coalesced with the increase in temperature (Figure 
3.3). But signals A and B never coalesced, confirming the presence of two different geometrical 
isomers (E- and Z-). In our modified conversion of 3.3 to 3.12 we used microwave irradiation at 
140 °C for 40 min instead of conventional heating to obtain 3.12 as a mixture of the E- and Z- 
isomers in 82% yield. Compound 3.12 was subsequently stirred with 5 equivalents of 
phosphorous oxychloride in DMF at room temperature for 8h, followed by simple work-up to get 
4-chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (3.2) as a white solid in 90% yield. We 
propose that the reaction proceeded through an intermediate iminium ion (3.13) formation by 
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initiating a regioselective electrophilic aromatic substitution at 4-position of 3.12, followed by a 
SNAr and elimination of DMF (Figure 3.4). Subsequent hydrolysis of 3.13 yielded the desired -
chloro aldehyde (3.2). The regioselectivity of the conversion was confirmed by IR, indicating the 
presence of a carbonyl stretching at 1646 cm
-1 
corresponding to the lactam. We found that 3.2 
was unstable at room temperature, but could be stored at -20 °C under inert atmosphere for a 
period of over six months.  
 
 
Figure 3.4. Plausible mechanism for the formation of 3.2 
Next, to explore the possible synthesis of ethyl 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-
2-carboxylate (3.14), we evaluated the reaction of 3.2 and ethyl 2-mercaptoacetate. The result of 
using different bases with different reaction conditions is shown in Table 3.2.  
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Table 3.2. Screening results of different bases for the synthesis of 3.14 
 
Entry Solvent Base Time Temperature 
(°C) 
Isolated yield 
(%) 
1 EtOH NaOEt 3h 80 0 
2 EtOH   Na2CO3 3h 80 48 
3 EtOH  K2CO3   24h 30 22 
4 EtOH  K2CO3 3h 80 88 
 
We found that potassium carbonate (K2CO3) was the base of choice for the optimum 
conversion. Although the mechanism of this reaction has not been established experimentally, 
we believe the reaction went through a tandem SNAr / cyclization, followed by elimination of 
water (Figure 3.5). To the best of our knowledge, this is the first efficient tandem SNAr / 
cyclization reaction to synthesize a C-ring substituted thienoquinolone moiety containing a free –
NH lactam. Hydrolysis of the ester (3.14) with lithium hydroxide and purification by a simple 
acid-base work-up produced the desired target 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-
carboxylic acid (2.14) in 96% yield. A detailed spectral characterization of 2.14 is established by 
using 
1
H NMR, 
13
C NMR, COSY, HSQC, HMBC, HRMS, IR and mp; purity is ascertained by 
HPLC analysis (see in appendices).  
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Figure 3.5. Plausible mechanism for tandem SNAr/cyclization to synthesize 3.14 
 
 
Scheme 3.9. Synthesis of 2.10 and 2.14  
 
Reagents and conditions: (i) Diethylmalonate, cat. DMF, 140 °C, 8 h, 95%; (ii) PPA, 150 °C, 3 
h, 70%; (iii) Triethyl orthoformate, aniline, ethylene glycol, mw, 145 °C, 20 min, 82%; (iv) 
POCl3, DMF, 8 h, 90%; (v) Ethyl 2-mercaptoacetate, K2CO3, anhyd EtOH, 80 °C, 3 h, 88%; (vi) 
LiOH, MeOH, H2O, 12 h, 96%; (vii) 5-Methylpyridin-2-amine, HBTU, iPr2NEt, DMF, 30 °C, 
12 h, 34%. 
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The overall syntheses of 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid 
(2.14) was achieved in six steps by using a sequence of Friedel–Crafts, Vilsmeier–Haack, SNAr 
and cyclization reactions (Scheme 3.9).
102
 We synthesized 2.10 by an activated ester coupling of 
2.14 with 5-methylpyridin-2-amine. Compound 2.14 was used as a suitable precursor to access 
the functionalization of the C-ring by convergent analog synthesis. Since 2.14 was a key 
compound, we decided to fully assign the 
1
H and 
13
C chemical shifts () from 1-D and 2-D 
NMR. The assignments are given in Table 3.3. 
 
Table 3.3. 
1
H and 
13
C NMR assignments of 2.14 
 
Position C (ppm) H (ppm) Multiplicity (J-
Values in Hz) 
HMBC 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
133.88 
130.27 
157.78 
 
116.38 
130.77 
122.65 
123.92 
130.94 
115.60 
137.14 
149.48 
162.52 
 
8.02 
 
11.86 
7.41 
7.53 
7.24 
7.87 
 
 
 
 
 
13.64 
 
s, 1H 
 
s, 1H, exchangeable 
d (8.4), 1H 
t (7.6), 1H 
t (7.6), 1H 
d (7.9), 1H 
 
 
 
 
 
s, 1H, exchangeable 
C
2
-HC
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The methyl ester (3.15) was synthesized by reacting 2.14 with TMS-diazomethane in 
81% yield. The synthesis of the amide derivatives was achieved by reacting the acid chloride, 
generated in-situ with the corresponding amines.
102
 We observed that a major by-product (3.38) 
was isolated in the reaction of the acid chloride with 2-aminopyridine (Scheme 3.10). This 
chlorinated product was observed only in case of the reaction with 2-aminopyridine, probably 
because of its strong basicity (pKa = 6.86). In certain cases where the substituted amides 
contained Boc-protection (3.23 and 3.25), the deprotection was carried out with HCl in dioxane 
to yield the HCl salts (3.24 and 3.26). The free carboxylic acid derivatives (3.34 and 3.36) were 
prepared by the saponification of the methyl esters (3.33 and 3.35) with aqueous NaOH.  
 
Scheme 3.10. Convergent syntheses of 3.15-3.39 
 
Reagents and conditions: (i) TMS diazomethane, CH2Cl2, MeOH, 81%;  (ii) Oxalyl chloride, 
CH2Cl2, 3h, 0-30°C; (iii) Amines, Hunig's base, CH2Cl2, 8h, 23-86%; (iv) 2-aminopyridine, 
Hunig's base, CH2Cl2, 8h, 23-30%. 
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The R-substitutions and the yield of the convergent-synthesized amides are described in 
Table 3.4. All compounds were characterized by 
1
H and 
13
C NMR, and HRMS and the purities 
determined by HPLC (see in appendices). 
 
Table 3.4. Isolated yield of the convergent syntheses amides 
 
Compound R X Y % yield 
3.16 -NH2 C=O NH 86 
3.17 -NH(iPr) C=O NH 80 
3.18 -NH(cyPr) C=O NH 71 
3.19 -NH(cyHex) C=O NH 81 
3.20 -NH(1-adamentyl) C=O NH 65 
3.21 
 
C=O NH 83 
3.22 
 
C=O NH 77 
3.23 
 
C=O NH 65 
3.24 
 
C=O NH 96
a
 
3.25 
 
C=O NH 75 
3.26  
C=O NH 92
a
 
3.27 
 
C=O NH 63 
3.28 
 
C=O NH 68 
3.29 
 
C=O NH 73 
3.30 
 
C=O NH 54 
3.31 
 
C=O NH 66 
3.32 
 
C=O NH 58 
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3.33 
 
C=O NH 88 
3.34 
 
C=O NH 92
b
 
3.35 
 
C=O NH 55 
3.36 
 
C=O NH 71
b
 
3.37 
 
C=O NH 30 
3.38 
 
=C-Cl N 23 
3.39 
 
C=O NH 41 
a
 Conversion yield represent the deprotection of the Boc- group from the preceding entries 
b
 Conversion yield represent the hydrolysis of the methyl-esters from the preceding entries 
 
3.3. Conclusions 
 
In summary, we developed an efficient one-step syntheses for 2,4-diamino thiazole 
derivative (2.14). We also developed one-step synthesis of the triazine derivative, 2.5. The major 
achievement of the project was the development of a cost-effective and efficient synthesis of 4-
oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14) achieved in six steps. Some 
interesting features were highlighted: high yields with no chromatographic purification, 
operational simplicity and novelty. We also demonstrated the ease of derivatization of 2.14, by 
synthesizing the convergent-synthesis analogs for SAR.   
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CHAPTER 4: EXPERIMENTAL OF THE SYNTHESIZED ANALOGS 
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Experimental Methods 
 
General 
Melting points were determined on an Opti-Melt automated melting point system 
(Stanford Research Systems) and are uncorrected. IR spectra were recorded using an Agilent 
model Cary 630 FT-IR. 
1
H and 
13
C NMR spectra were obtained on Bruker model AMX 500 and 
Avance 400 NMR spectrometers with standard pulse sequences, operating at 500 and 400 MHz 
for 
1
H and 125 and 100 MHz for 
13
C. The residual DMSO-d6 solvent signals (DMSO-d6: H = 
2.50 ppm and C = 39.51 ppm) were used as an internal reference. The chemical shifts ( were 
expressed in ppm. Multiplicities were described as singlet (s), doublet (d), triplet (t), multiplet 
(m) and broad resonance (br). The coupling constants (J) were expressed in Hz. Low-resolution 
mass spectra (LRMS) were recorded on a Waters Micromass Quattro micro™ spectrometer with 
electro spray ionization (ESI) interface. High-resolution mass spectra (HRMS) were recorded on 
either a Bruker Daltonics micro-TOF mass spectrometer or a Micromass Q-TOF Agilent 
G1969A mass spectrometer with ESI interface. R (-) roscovitine (1) was purchased from Enzo 
Life Sciences (www.enzolifesciences.com). 1-(4-(((4-chlorophenyl)thio)methyl)-6-
hydroxypyrimidin-2-yl)-3-(4-methoxyphenyl)guanidine (6) and 4-(4,6-dimethyl-2-(pyridin-2-
yl)-1H-indol-3-yl)butanoic acid (11) were purchased from ChemBridge (www.chembridge.com)  
N-(5-((2-oxo-2-(p-tolylamino)ethyl)thio)-1,3,4-thiadiazol-2-yl)-3-phenylpropanamide (7), N-(3-
(1H-pyrazol-1-yl)propyl)-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide (8) and 2-((4-((4-
methoxyphenyl)amino)pteridin-2-yl)amino)ethanol (12) were purchased from Ryan Scientific, 
Inc. (https://ryansci.com). 2-((3-(4-Methoxybenzyl)-4-oxo-3,4-dihydropteridin-2-yl)thio)-N-(3-
methyl-1H-pyrazol-5-yl)acetamide  (9) and 2-((4-((3,4-dimethylphenyl)amino)-1-phenyl-1H-
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pyrazolo[3,4-d]pyrimidin-6-yl)amino)ethanol (13) were purchased from ChemDiv 
(www.chemdiv.com). All the purchased standards were characterized by 
1
H NMR and HRMS. 
The purity was checked by HPLC and found to have purity of >95%. Column chromatography 
was carried out on silica gel (70-230 mesh, Merck). TLC was performed on silica gel 60 F254 
plates. Anhydrous DMF and CH2Cl2 were purchased in sure-seal® bottles from Aldrich. All the 
reagents were used without further purification unless otherwise noted. A Biotage® Initiator 
microwave was used for all microwave (MW) reactions. All the HPLC analysis were performed 
on Waters W2690/5, attached with a 996 PDA detector, using X-tera C-18, 3x100 column and 
using a gradient system (Table 3.1) consisting of water (0.1% formic acid) and acetonitrile (0.1% 
formic acid). 
 
Table 4.1. Gradient-mix used for HPLC purity determination  
Time (min) Flow (mL/min) % water % acetonitrile 
0.00 0.30 90.0 10.0 
2.00 0.30 90.0 10.0 
22.00 0.30 5.0 95.0 
23.00 0.30 0.0 100.0 
25.00 0.30 0.0 100.0 
27.00 0.30 90.0 10.0 
42.00 0.30 90.0 10.0 
43.00 0.00 90.0 10.0 
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Synthesis of (4-amino-2-((4-chlorophenyl)amino)thiazol-5-yl)(3-nitrophenyl) methanone 
(2.4).  
 
 To a stirred suspension of cyanamide (0.0505g, 1.2 mmol) in 40 mL of CH3CN was 
added 4-chlorophenyl isothiocyanate (3.5) (0.17 g, 1 mmol) in 5 mL of butanol and KOtBu 
(0.135 g, 1.2 mmol). The mixture was stirred at ambient temperature for 30 min and a suspension 
of 2-bromo-3′-nitroacetophenone (3.6) (0.6 g, 2.9 mmol) in 10 mL of CH3CN was added and 
stirred for 2h. The precipitated solid was triturated with water, extracted with EtOAc and layers 
were separated. The organics were extracted with saturated brine, dried over anhydrous Na2SO4, 
filtered, and purified on silica gel using CH2Cl2:EtOAc (8:2) to yield the title compound as a 
yellow solid (0.22 g, 59%). 
1H NMR (400 MHz, DMSO) δ 11.02 (s, 1H), 8.45 (s, 2H, ex), 8.40 
(s, 1H, ex), 8.35 (d, J = 8.3 Hz, 2H), 8.14 (d, J = 7.5 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.68 (d, J 
= 8.3 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H). 
13C NMR (100 MHz, DMSO) δ 179.42, 166.89, 166.27, 
147.65, 142.74, 138.35, 133.20, 130.35, 128.96, 127.03, 125.07, 121.41, 120.48, 92.22. HRMS 
(ESI-TOF) m/z calcd for C16H10ClN4O3S [M-H]¯: 373.0162. Found: 373.0164. HPLC: retention 
time 19.27 min; purity >99%. 
Synthesis of 2-((4-((4-chlorophenyl)amino)-6-methoxy-1,3,5-triazin-2-yl)amino) ethanol 
(2.5).  
 
To a stirred solution of 2,4-dichloro-6-methoxy-1,3,5-triazine (3.7) (0.4 g, 2.22 mmol) 
and Hunig’s base (0.43 g, 3.33 mmol)  in 50 mL of CH2Cl2 at 0 °C was added 4-chloroaniline 
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(0.34 g, 2.66 mmol). The mixture was stirred at ambient temperature for 30 min and a solution of 
ethanol amine (212 L, 2.66 mmol) and Hunig’s base (0.43 g, 3.33 mmol) in 40 mL of CH2Cl2 
was added to the reaction mixture. The mixture was stirred for 8h and monitored by TLC. It was 
then concentrated in vacuo, diluted with EtOAc and extracted with saturated NaHCO3. The 
organics were extracted with saturated brine, dried over anhydrous Na2SO4, filtered, and purified 
over silica gel using CH2Cl2:EtOAc (8:2) to yield the title compound as a white solid (0.461 g, 
70%). 
1H NMR (400 MHz, DMSO) δ 9.79 – 9.40 (m, 1H, ex), 7.77 (d, J = 8.7 Hz, 2H), 7.43 
(brs, 1H), 7.31 (d, J = 8.7 Hz, 2H), 4.68 (d, J = 5.1 Hz, 1H, ex), 3.81 (s, 3H), 3.61 – 3.44 (m, 
2H), 3.42 – 3.33 (m, 2H). 13C NMR (100 MHz, DMSO) δ 170.36, 166.84, 165.10, 138.92, 
128.23, 125.48, 121.15, 59.64, 53.58, 42.88. HRMS (ESI-TOF) m/z calcd for C12H13ClN5O2 [M-
H]¯: 294.0758. Found: 294.0783. HPLC: retention time 13.57 min; purity >99%. 
Synthesis of methyl 2-aminobenzoate (3.9) 
 
 To a stirred suspension of anthranilic acid (3.8) (3.8 g, 27.7 mmol) in 50 mL of MeOH 
was added conc. H2SO4 (2 mL) and the mixture was refluxed for 12h and monitored by TLC. It 
was then concentrated in vacuo, diluted with EtOAc and neutralized with saturated NaHCO3. 
The organics were separated and extracted with saturated brine, dried over anhydrous Na2SO4, 
filtered, and purified over silica gel using hexane:EtOAc (95:5) to yield the title compound as a 
white solid (2.69 g, 64%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 8.0 Hz, 1H), 7.24 (t, J = 
7.7 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.63 (s, 2H), 6.52 (t, J = 7.5 Hz, 1H), 3.78 (s, 3H). MS 
(ESI) m/z calcd for C8H10NO2 [M+H]
+
: 152.07. Found 152.41. 
Synthesis of methyl 2-acetamidobenzoate (3.10) 
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 To a stirred solution of methyl 2-aminobenzoate (3.9) (1.0 g, 6.6 mmol) in 20 mL of 
dioxane was added acetic anhydride (10 mL) and the mixture was refluxed for 2h and monitored 
by TLC. It was then concentrated in vacuo, diluted with EtOAc and neutralized with saturated 
NaHCO3. The organics were separated and extracted with saturated brine, dried over anhydrous 
Na2SO4, filtered, and purified over silica gel using hexane:EtOAc (95:5) to yield the title 
compound as a white solid (0.715 g, 56%). 
1
H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.21 
(d, J = 8.3 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 
3.85 (s, 3H), 2.11 (s, 3H). MS (ESI) m/z calcd for C10H12NO3 [M+H]
+
: 194.08. Found 194.47. 
Alternate synthesis of 4-hydroxyquinolin-2(1H)-one (3.3): 
 
 To a stirred solution of methyl 2-acetamidobenzoate (3.10) (0.7 g, 3.62 mmol) in 50 mL 
of THF was added a solution of potassium bis(trimethylsilyl)amide in toluene (20 mL, 10 mmol) 
at -78 °C under argon. The mixture was then allowed to warm to the ambient temperature for 
12h. The mixture was quenched by pouring into ice-water. The aqueous layer was washed with 
EtOAc (10 mL). The aqueous fraction was acidified with 1N HCl to precipitate the desired 
product, which was filtered, washed with water and dried under vacuum to yield the title 
compound as a white solid (0.23 g, 40%).
1
H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 11.17 
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(s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 7.13 (t, J = 
7.6 Hz, 1H), 5.75 (s, 1H). MS (ESI) m/z calcd for C9H8NO2 [M+H]
+
: 162.05. Found 162.35. 
m/z calcd for C9H7NNaO2 [M+23]
+
: 184.04. Found 184.33 
Synthesis of N
1
,N
3
-diphenylmalonamide (3.11): 
 
Catalytic amount of DMF was added to a stirred solution of aniline (3.4) (10 g, 108 
mmol) and diethyl malonate (8.7 g, 54 mmol). The reaction mixture was heated at 140 °C for 8h. 
The precipitated solid was filtered and washed with Et2O to produce the title compound as a 
white solid (13.03 g, 95%); mp 228-229 °C; FTIR νmax (cm
-1
): 3268, 3147, 1667, 1643, 1595, 
1531, 1497, 1413, 1354, 1248, 1192, 979;  
1
H- NMR (400 MHz, DMSO-d6) δ 10.16 (s, 2H), 7.60 
(d, J = 7.9 Hz, 4H), 7.32 (t, J = 7.9 Hz), 7.06 (t, J = 7.4 Hz), 3.47 (s, 2H). 
13
C-NMR (100 MHz, 
DMSO-d6) δ 165.41, 138.95, 128.75, 123.37, 119.07, 45.94. HRMS (ESI-TOF) m/z calcd for 
C15H15N2O2 [M+H]
+
: 255.1134. Found: 255.1144. 
Synthesis of 4-hydroxyquinolin-2(1H)-one (3.3): 
 
N
1
,N
3
-diphenylmalonamide (3.11) (12.76 g, 50 mmol) was added in portions to a stirred 
solution of PPA (50 g) at 150 °C and stirred for 3h. It was then quenched by pouring onto ice-
water, resulting in precipitation. The solid was filtered and dissolved into 200 mL of 1N NaOH. 
Any undissolved solid was removed by filtration. The filtrate was acidified with 1N HCl to 
precipitate the desired product, which was filtered, washed with water and dried under vacuum to 
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yield the title compound as a white solid (6.01 g, 74%); mp 329-330 °C (dec); FTIR νmax (cm
-1
): 
3090, 2984, 2854, 649, 1634, 1591, 1414, 1233, 860, 753; 
1
H NMR (400 MHz, DMSO-d6) δ 
11.28 (br s, 1H), 11.18 (s, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 8.2 
Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 5.73 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6) δ 163.60, 
162.47, 139.19, 130.84, 122.66, 121.05, 115.13, 115.02, 98.24, 83.17. HRMS (ESI-TOF) m/z 
calcd for C9H8NO2 [M+H]
+
: 162.0555. Found: 162.0550. 
Synthesis of 3-((phenylamino)methylene)quinoline-2,4(1H,3H)-dione (3.12):  
 
To a microwave vial containing aniline (0.38 g, 4.04 mmol) and triethylorthoformate (0.6 
g, 4.04 mmol) in 10 mL of ethylene glycol was added 4-hydroxyquinolin -2(1H)-one (3.3). The 
reaction mixture was heated in a microwave at 140 °C for 40 min. The precipitated solid was 
filtered and washed with EtOH to produce the title compound as a mixture of E- and Z- isomers 
(0.87 g, 82%); 
1
H NMR (400 MHz, DMSO- d6) δ 13.70 (d, J = 12.5 Hz), 12.81 (d, J = 12.5 Hz), 
10.94 (s), 10.87 (s), 8.88 (d, J = 12.0 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.63 – 7.43 (m, 5H), 7.30 
(t, J = 6.9 Hz, 1H), 7.24 – 7.08 (m, 2H). 13C NMR (125 MHz, DMSO- d6) δ 181.72, 178.87, 
165.85, 163.30, 152.96, 152.30, 141.27, 140.73, 138.44, 138.32, 133.79, 133.68, 129.92, 129.86, 
126.40, 126.15, 125.97, 125.53, 121.70, 121.42, 120.35, 119.63, 118.66, 118.62, 118.49, 116.16, 
115.87, 103.02, 102.32. HRMS (ESI-TOF) m/z calcd for C15H15N2O2 [M+H]
+
: 265.0977. Found: 
265.0949. 
Synthesis of 4-chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (3.2): 
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To a stirred solution of 3-((phenylamino)methylene)quinoline-2,4(1H,3H)-dione (3.12) 
(0.87 g, 3.29 mmol) in 10 mL of DMF at 0 °C was added POCl3 (2.5 g, 16.5 mmol). The reaction 
mixture was stirred at 0 °C for 15 min and then stirred at ambient temperature for 8h. It was then 
quenched by pouring onto ice-water, resulting in precipitation. The solid was filtered, washed 
with Et2O and dried under vacuum to yield the title compound as a yellow solid (0.61 g, 90%); 
mp 258-259 °C (dec); FTIR νmax (cm
-1
): 3156, 2981, 2854, 2716, 1701, 1646, 1612, 1587, 1538, 
1479, 1436, 1235, 960, 750; 
1
H NMR (400 MHz, DMSO-d6) δ 12.42 (s, 1H), 10.29 (s, 1H), 8.06 
(d, J = 8.3 Hz, 1H), 7.70 (t, J = 7.7 Hz, 1H), 7.50 – 7.26 (m, 2H); 13C NMR (100 MHz, DMSO-
d6) δ 189.33, 160.37, 146.27, 139.54, 134.12, 126.66, 123.33, 122.71, 117.43, 115.92. HRMS 
(ESI-TOF) m/z calcd for C10H5ClNO2 [M-H]¯: 206.0009. Found: 206.0071. 
Synthesis of ethyl 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylate (3.14): 
 
To a stirred suspension of K2CO3 (1.2 g, 8.7 mmol) in 20 mL of anhydrous EtOH, was 
added ethyl 2-mercaptoacetate (0.52 g, 4.35 mmol). The reaction was stirred for 10 min and a 
suspension of 4-chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (3.2) (0.6 g, 2.9 mmol) in 10 
mL of EtOH was added and stirred at 80 °C for 3h. The precipitated solid was filtered, triturated 
with water, re-filtered, washed with EtOH and dried to yield the title compound as a white solid 
(0.7 g, 88%); mp 315-317 °C (dec); FTIR νmax (cm
-1
): 3020, 2875, 1711, 1655, 1589, 1513, 1467, 
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1366, 1284, 1246, 1153, 1071, 745; 
1
H NMR (400 MHz, DMSO-d6) δ 11.92 (s, 1H, H
5
), 8.10 (s, 
1H, H
3
), 7.94 (d, J = 7.7 Hz, 1H, H
9
), 7.57 (t, J = 7.3 Hz, 1H, H
7
), 7.43 (d, J = 8.0 Hz, 1H, H
6
), 
7.27 (t, J = 7.1 Hz, 1H, H
8
), 4.36 (q, J = 6.4 Hz, 2H, H
16
), 1.35 (t, J = 6.7 Hz, 3H, H
17
). 
13
C NMR 
(100 MHz, DMSO-d6) δ 160.79, 157.48, 149.53, 137.13, 131.91, 130.72, 130.58, 123.73, 122.48, 
116.25, 115.33, 61.41, 13.87. HRMS (ESI-TOF) m/z calcd for C14H12NO3S [M+H]
+
: 274.0538. 
Found: 274.0536. HPLC: retention time 19.26 min; purity >99%. 
Synthesis of 5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14): 
 
To a stirred suspension of ethyl 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylate 
(3.14) (1.28 g, 4.68 mmol) in 50 mL of (1:1) MeOH-H2O was added LiOH (0.5 g, 11.71 mmol). 
The mixture was stirred for 12h, filtered and the filtrate was concentrated in vacuo to evaporate 
the MeOH. Acidification with 6N HCl yielded the title compound as a white precipitate. The 
solid was filtered, washed with water and Et2O and dried to yield the title compound as a white 
solid (1.1 g, 96%); mp 371 °C; FTIR νmax (cm
-1
): 3090, 2983, 2067, 1685, 1644, 1587, 1541, 
1404, 1159, 839, 743;  
1
H NMR (400 MHz, DMSO-d6) δ 13.64 (s, 1H, H
15
), 11.86 (s, 1H, H
5
), 
8.02 (s, 1H, H
3
), 7.87 (d, J = 7.9 Hz, 1H, H
9
), 7.53 (t, J = 7.6 Hz, 1H, H
7
), 7.41 (d, J = 8.4 Hz, 
1H, H
6
), 7.24 (t, J = 7.6 Hz, 1H, H
8
). 13C NMR (100 MHz, DMSO- d6) δ 162.52 (C
14
), 157.78 
(C
4
), 149.48 (C
13
), 137.14(C
12
), 133.88 (C
2
), 130.94 (C
10
), 130.77 (C
7
), 130.27 (C
3
), 123.92 (C
9
), 
122.65 (C
8
), 116.38 (C
6
), 115.60 (C
11
). HRMS (ESI-TOF) m/z calcd for C12H8NO3S [M+H]
+
: 
246.0225. Found: 246.0244. HPLC: retention time 12.58 min; purity >99%. 
N-(5-methylpyridin-2-yl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (2.10).  
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 To a stirred suspension of 5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14) (0.18 
g, 0.73 mmol) in 10 mL of DMF was added HBTU (0.279 g, 0.73 mmol) and Hunig’s base 
(0.472 g, 3.65 mmol). The mixture was stirred at ambient temperature for 30 min and a solution 
of 5-methylpyridin-2-amine (0.118g, 1.1 mmol) in 2 mL of DMF was added to the reaction 
mixture. The mixture was stirred for 8h and monitored by TLC. It was then concentrated in 
vacuo to a slurry, filtered through a Strata™ X-C pre-packed column and purified over silica gel 
using CH2Cl2:MeOH with 1% NH3 (95:5) to yield the title compound as a white solid (0.083 g, 
34%). 
1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H, ex, H5), 11.20 (s, 1H, ex, H15), 8.75 (s, 1H, 
H
3
), 8.25 (s, 1H, H
18
), 8.03 (d, J = 8.4 Hz, 1H, H
9
), 7.92 (d, J = 7.9 Hz, 1H, H
21
), 7.67 (d, J = 8.4 
Hz, 1H, H
20
), 7.55 (t, J = 7.7 Hz, 1H, H
7
), 7.43 (d, J = 8.3 Hz, 1H, H
6
), 7.26 (t, J = 7.6 Hz, 1H, 
H
8
), 2.29 (s, 3H, H
22
). 13C NMR (125 MHz, DMSO) δ 159.79, 157.93, 149.41, 148.80, 147.78, 
138.92, 138.49, 136.97, 131.53, 130.57, 129.05, 127.65, 124.02, 122.60, 116.32, 115.66, 114.46, 
17.30. HRMS (ESI-TOF) m/z calcd for C18H14N3O2S [M+H]
+
: 336.0807. Found: 336.0818. 
HPLC: retention time 14.29 min; purity >99%. 
Synthesis of methyl 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxylate (3.15): 
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TMS-diazomethane (150 L, 0.3 mmol) was added drop-wise to a stirred suspension of 
5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14) (0.025g, 0.1 mmol) in a mixture of 5 
mL of CH2Cl2 and 1 mL of MeOH. The reaction mixture was stirred for 3h and monitored by 
TLC. It was then quenched with few drops of AcOH and stirred for an additional 2h, 
concentrated in vacuo to dryness and purified by column chromatography on silica gel to give 
the title compound as a white solid (0.021 g, 81%); mp 314-316 °C; FTIR νmax (cm
-1
): 2877, 
1718, 1591, 1468, 1430, 1286, 1251, 1153, 1071, 702; 
1
H NMR (400 MHz, DMSO-d6) δ 11.91 
(s, 1H, H
5
), 8.08 (s, 1H, H
3
), 7.91 (d, J = 7.9 Hz, 1H, H
9
), 7.56 (t, J = 7.6 Hz, 1H, H
7
), 7.42 (d, J 
= 8.2 Hz, 1H, H
6
), 7.26 (t, J = 7.0 Hz, 1H, H
8
), 3.90 (s, 3H, H
16
). 
13
C NMR (125 MHz, DMSO-
d6) δ 161.51, 157.72, 149.83, 137.28, 131.71, 131.10, 130.91, 124.09, 122.79, 116.46, 115.47, 
52.85. HRMS (ESI-TOF) m/z calcd for C13H8NO3S [M-H]¯: 258.0225. Found: 258.0234. HPLC: 
retention time 14.60 min; purity >99%. 
General procedure for synthesis of carboxamides (3.16-3.23, 3.25, 3.27-3.33, 3.35, 
3.37-3.39): 
To a stirred suspension of 5-dihydrothieno[3,2-c]quinoline-2-carboxylic acid (2.14) 
(0.025g, 0.1 mmol) in 5 mL of CH2Cl2 was added oxalyl chloride (0.02 g, 0.15 mmol) and 2 
drops of DMF. The reaction mixture was stirred for 2h and then concentrated in vacuo. The dried 
suspension of the acid chloride in 10 mL of CH2Cl2 was added to a stirred solution of the 
respective amines (0.03 mmol) and Hunig’s base (in 5 mL of CH2Cl2) and the reaction mixture 
was stirred for 12h. It was then concentrated to dryness and purified on silica gel column to give 
the title compounds. 
4-Oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.16):  
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White solid (86%); mp 334 °C (dec); FTIR νmax (cm
-1
): 3206, 3086, 1662, 1616, 1518, 
1423, 1374, 1106, 747; 
1
H NMR (400 MHz, DMSO-d6) δ 11.79 (s, 1H, H
5
), 8.30 (s, 2H, H
3,15
), 
7.88 (d, J = 7.9 Hz, 1H, H
9
), 7.66 (s, 1H, H
15
), 7.53 (t, J = 7.7 Hz, 1H, H
6
), 7.43 (d, J = 8.3 Hz, 
1H, H
7
), 7.25 (t, J = 7.6 Hz, 1H, H
8
). 13C NMR (125 MHz, DMSO-d6) δ 162.38, 157.99, 148.12, 
139.86, 136.79, 131.33, 130.30, 126.20, 123.81, 122.57, 116.30, 115.80. HRMS (ESI-TOF) m/z 
calcd for C12H7N2O2S [M-H]¯: 243.0228. Found: 243.0248. HPLC: retention time 11.09 min; 
purity >99%. 
N-Isopropyl-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.17): 
 
White solid (80%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H, H
5
), 8.62 (d, J = 8.1 
Hz, 1H, H
15
), 8.36 (s, 1H, H
3
), 7.88 (d, J = 8.2 Hz, 1H, H
9
), 7.53 (t, J = 8.0 Hz, 1H, H
7
), 7.43 (d, 
J = 8.4 Hz, 1H, H
6
), 7.25 (t, J = 7.9 Hz, 1H, H
8
), 4.50 – 3.70 (m, 1H, H16), 1.19 (d, J = 6.8 Hz, 
6H, H
17,18
). 
13
C NMR (125 MHz, DMSO-d6) δ 159.66, 158.06, 147.76, 139.99, 136.78, 131.29, 
130.30, 125.43, 123.84, 122.64, 116.35, 115.86, 41.40, 22.27. HRMS (ESI-TOF) m/z calcd for 
C15H13N2O2S [M-H]¯: 285.0698. Found: 285.0692. HPLC: retention time 13.70 min; purity 
>98%. 
N-Cyclopropyl-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.18): 
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White solid (71%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H, H
5
), 8.81 (s, 1H, H
15
), 
8.28 (s, 1H, H
3
), 7.89 (d, J = 8.1 Hz, 1H, H
9
), 7.53 (t, J = 7.9 Hz, 1H, H
7
), 7.43 (d, J = 8.4 Hz, 
1H, H
6
), 7.25 (t, J = 7.6 Hz, 1H, H
8
), 2.94 - 2.76 (m, 1H, H
16
), 0.82 - 0.50 (m, 4H, H
17,18
). 
13
C 
NMR (100 MHz, DMSO-d6) δ 161.72, 158.00, 147.82, 139.47, 136.78, 131.28, 130.34, 125.54, 
123.85, 122.63, 116.33, 115.80, 23.05, 5.72. HRMS (ESI-TOF) m/z calcd for C15H11N2O2S [M-
H]¯: 283.0541. Found: 283.0549. HPLC: retention time 14.19 min; purity >96%. 
3.2.15.4.  N-Cyclohexyl-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.19): 
 
White solid (81%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H, H
5
), 8.62 (d, J = 8.0 
Hz, 1H, H
15
), 8.38 (s, 1H, H
3
), 7.88 (d, J = 7.9 Hz, 1H, H
9
), 7.53 (t, J = 7.7 Hz, 1H, H
7
), 7.43 (d, 
J = 8.2 Hz, 1H, H
6
), 7.25 (t, J = 7.6 Hz, 1H, H
8
), 4.13 – 3.54 (m, 1H, H16), 1.92 – 1.70 (m, 4H, 
H
17,21
), 1.61 (d, J = 12.7 Hz, 1H, H
19
), 1.40 – 1.22 (m, 4H, H18,20), 1.21 – 1.09 (m, 1H, H19). 13C 
NMR (100 MHz, DMSO-d6) δ 159.60, 158.07, 147.78, 140.01, 136.79, 131.31, 130.31, 125.49, 
123.87, 122.64, 116.35, 115.87, 48.64, 32.38, 25.21, 24.86. HRMS (ESI-TOF) m/z calcd for 
C18H17N2O2S [M-H]¯:  325.1011. Found: 327.1019. HPLC: retention time 15.16 min; purity 
>98%. 
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N-((3s,5s,7s)-Adamantan-1-yl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide 
(3.20): 
 
White solid (65%); 
1
H NMR (500 MHz, DMSO-d6) δ 11.76 (s, 1H, H
5
), 8.44 (s, 1H, H
15
), 
8.07 (s, 1H, H
3
), 7.87 (d, J = 7.8 Hz, 1H, H
9
), 7.52 (t, J = 7.7 Hz, 1H, H
7
), 7.42 (d, J = 8.1 Hz, 
1H, H
6
), 7.25 (t, J = 7.6 Hz, 1H, H
8
), 2.23 – 1.99 (m, 9H, H17, 18,20,22-24), 1.78 – 1.57 (m, 6H, 
H
19,21,25
). 
13
C NMR (125 MHz, DMSO-d6) δ 159.99, 158.08, 147.63, 141.16, 136.75, 131.29, 
130.24, 125.71, 123.86, 122.60, 116.31, 115.87, 52.16, 40.84, 36.00, 28.89. HRMS (ESI-TOF) 
m/z calcd for C22H21N2O2S [M-H]¯:  377.1324. Found: 377.1317. HPLC: retention time 18.37 
min; purity >99%. 
N-(2-Hydroxyethyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.21):  
 
White solid (83%); mp 307-309 °C; FTIR νmax (cm
-1
): 3358, 2820, 1655, 1624, 1548, 
1434, 1300, 1255, 1064, 903, 708; 
1
H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H, H
5
), 8.84 (s, 
1H, H
15
), 8.32 (s, 1H, H
3
), 7.89 (d, J = 7.8 Hz, 1H, H
9
), 7.53 (t, J = 7.6 Hz, 1H, H
7
), 7.43 (d, J = 
8.1 Hz, 1H, H
6
), 7.25 (t, J = 7.4 Hz, 1H, H
8
), 4.77 (t, J = 4.8 Hz, 1H, H
18
), 3.53 (q, J = 5.1 Hz, 
2H, H
16
), 3.33 (q, J = 5.7 Hz, 2H, H
17
). 
13
C NMR (125 MHz, DMSO-d6) δ 160.73, 158.07, 
147.83, 139.73, 136.82, 131.34, 130.38, 125.54, 123.91, 122.67, 116.37, 115.85, 59.58, 42.30. 
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HRMS (ESI-TOF) m/z calcd for C14H13N2O3S [M+H]
+
: 289.0647. Found: 289.0627. HPLC: 
retention time 10.95 min; purity >99%. 
N-(3-Hydroxypropyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.22) 
 
White solid (77%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.69 (s, 1H, H
5
), 8.81 (br s, 1H, 
H
15
), 8.30 (s, 1H, H
3
), 7.88 (d, J = 7.9 Hz, 1H, H
9
), 7.53 (t, J = 7.8 Hz, 1H, H
7
), 7.43(d, J = 8.3 
Hz, 1H, H
6
), 7.25 (t, J = 7.6 Hz, 1H, H
8
), 4.48 (br s, 1H, H
19
), 3.48 (m, 2H, H
18
), 3.32 
(overlapped, 2H, H
16
), 1.70 (m, 2H, H
17
). 
13
C NMR (100 MHz, DMSO-d6) δ 160.53, 158.00, 
147.74, 139.72, 136.77, 131.29, 130.28, 125.31, 123.81, 122.60, 116.32, 115.81, 58.45, 36.66, 
32.26. HRMS (ESI-TOF) m/z calcd for C12H7N2O2S [M-H]¯: 301.0647. Found: 301.0640. 
HPLC: retention time 11.31 min; purity >99%. 
tert-Butyl(2-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)ethyl) carbamate 
(3.23) 
 
 
White solid (65%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H, H
5
), 8.82 (t, J = 5.9 
Hz, 1H, H
15
), 8.28 (s, 1H, H
3
), 7.89 (d, J = 7.9 Hz, 1H, H
9
), 7.53 (t, J = 7.7 Hz, 1H, H
7
), 7.43(d, J 
= 8.3 Hz, 1H, H
6
), 7.25 (t, J = 7.5 Hz, 1H, H
8
), 6.92 (t, J = 6.1 Hz, 1H, H
18
), 3.29 (overlapped, 
2H, H
17
), 3.12 (d, J = 6.4 Hz, 2H, H
16
), 1.37 (s, 9H, H
22,23,24
). 
13
C NMR (125 MHz, DMSO-d6) δ 
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160.74, 158.01, 155.68, 147.82, 136.80, 131.24, 130.34, 125.62, 123.85, 122.65, 116.35, 115.81, 
77.72, 39.51 (overlapped), 28.22. HRMS (ESI-TOF) m/z calcd for C12H7N2O2S [M-H]¯: 
386.1175. Found: 386.1171. 
tert-butyl (3-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)propyl) carbamate 
(3.25)  
 
White solid (75%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H, H
5
), 8.80 (t, J = 5.7 
Hz, 1H, H
15
), 8.29 (s, 1H, H
3
), 7.89 (d, J = 8.0 Hz, 1H, H
9
), 7.53 (t, J = 7.7 Hz, 1H, H
7
), 7.43 (d, 
J = 8.3 Hz, 1H, H
6
), 7.25 (t, J = 7.6 Hz, 1H, H
8
), 6.82 (t, J = 6.1 Hz, 1H, H
19
), 3.27 (m, 2H, H
18
), 
2.99 (m, 2H, H
16
), 1.65 (m, 2H, H
17
), 1.37 (s, 9H, H
23,24,25
). 
13
C NMR (100 MHz, DMSO-d6) δ 
160.51, 158.00, 155.57, 147.78, 139.59, 136.79, 131.28, 130.31, 125.37, 123.82, 122.62, 116.33, 
115.81, 77.48, 37.73, 37.14, 29.39, 28.24. HRMS (ESI-TOF) m/z calcd for C12H7N2O2S [M-H]¯: 
400.1331. Found: 400.1320. 
4-oxo-N-phenyl-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.27):  
 
White solid (63%); mp 321-322 °C (dec); FTIR νmax (cm
-1
): 2728, 1638, 1536, 1512, 
1321, 1254, 905, 749; 
1
H NMR (400 MHz, DMSO-d6) δ 11.83 (s, 1H, H
5
), 10.55 (s, 1H, H
15
), 
8.64 (s, 1H, H
3
), 7.93 (d, J = 7.5 Hz, 1H, H
9
), 7.78 (d, J = 7.8 Hz, 2H, H
17,21
), 7.55 (t, J = 7.7 Hz, 
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1H, H
7
), 7.44 (d, J = 8.1 Hz, 1H, H
6
), 7.37 (t, J = 7.9 Hz, 2H, H
18,20
), 7.27 (t, J = 7.3 Hz, 1H, H
8
), 
7.13 (t, J = 7.4 Hz, 1H, H
19
). 
13
C NMR (100 MHz, DMSO-d6) δ 159.33, 158.03, 148.54, 139.47, 
138.50, 136.93, 131.36, 130.57, 128.74, 126.75, 123.99, 122.69, 120.21, 116.39, 115.74. HRMS 
(ESI-TOF) m/z calcd for C18H12N2O2S [M-H]¯: 319.0541. Found: 319.0539. HPLC: retention 
time 16.71 min; purity >99%. 
N-(4-fluorophenyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.28): 
 
White solid (68%); 
1
H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H, H
5
), 10.61 (s, 1H, 
H
15
), 8.61 (s, 1H, H
3
), 7.93 (d, J = 7.9 Hz, 1H, H
9
), 7.80 (dd, J = 8.7, 4.9 Hz, 2H, H
17,21
), 7.56 (t, 
J = 7.8 Hz, 1H, H
7
), 7.45 (d, J = 8.3 Hz, 1H, H
6
), 7.32 – 7.18 (m, 3H, H8,18,20). 13C NMR (125 
MHz, DMSO-d6) δ 159.26, 158.01, 148.56, 139.22, 136.93, 134.86, 131.34, 130.59, 126.77, 
124.01, 122.71, 122.09, 122.03, 116.39, 115.72, 115.45, 115.28. HRMS (ESI-TOF) m/z calcd for 
C18H10FN2O2S [M-H]¯: 337.0447 Found: 337.0455. HPLC: retention time 15.47 min; purity 
>97%. 
N-(3-fluorophenyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.29): 
64 
 
 
White solid (73%); 
1
H NMR (500 MHz, DMSO-d6) 11.87 (s, 1H, H
5
), 10.72 (s, 1H, H
15
), 
8.64 (s, 1H, H
3
), 7.94 (d, J = 7.9 Hz, 1H, H
9
), 7.74 (d, J = 11.7 Hz, 1H, H
17
), 7.62 – 7.52 (m, 2H, 
H
7,21
), 7.49 – 7.37 (m, 2H, H6,20), 7.28 (t, J = 7.5 Hz, 1H, H8), 6.97 (t, J = 8.5 Hz, 1H, H19). 13C 
NMR (125 MHz, DMSO-d6) 163.01, 161.09, 159.61, 158.04, 148.84, 140.32, 140.23, 138.92, 
136.99, 131.35, 130.71, 130.48, 130.41, 127.16, 124.08, 122.76, 116.44, 115.89, 115.71, 110.56, 
110.40, 107.01, 106.80. HRMS (ESI-TOF) m/z calcd for C18H10FN2O2S [M-H]¯: 337.0447 
Found: 337.0450. HPLC: retention time 16.08 min; purity >97%. 
N-(2,4-difluorophenyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide 
(3.30): 
 
White solid (54%); 
1
H NMR (500 MHz, DMSO-d6) 11.85 (s, 1H, H
5
), 10.53 (s, 1H, H
15
), 
8.56 (s, 1H, H
3
), 7.93 (d, J = 7.9 Hz, 1H, H
9
), 7.65 – 7.53 (m, 2H, H7,21), 7.45 (d, J = 8.2 Hz, 1H, 
H
6
), 7.43 – 7.35 (m, 1H, H18), 7.27 (t, J = 7.5 Hz, 1H, H8), 7.15 (t, J = 8.7 Hz, 1H, H20). 13C 
NMR (125 MHz, DMSO-d6) 159.73, 158.04, 148.77, 138.21, 137.02, 131.40, 130.74, 128.65, 
127.34, 124.12, 122.80, 116.46, 115.74, 111.53, 111.35, 104.79, 104.59, 104.39. HRMS (ESI-
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TOF) m/z calcd for C18H9F2N2O2S [M-H]¯: 355.0353 Found: 355.0351. HPLC: retention time 
15.10 min; purity >97%. 
N-benzyl-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.31): 
 
White solid (66%); 
1
H NMR (400 MHz, DMSO-d6) 11.79 (s, 1H, H
5
), 9.41 (s, 1H, H
15
), 
8.37 (s, 1H, H
3
), 7.90 (d, J = 7.1 Hz, 1H, H
9
), 7.61 – 7.13 (m, 8H, H6-8,18-22), 4.49 (d, J = 6.1 Hz, 
2H, H
16
). 
13
C NMR (125 MHz, DMSO-d6) 160.65, 158.02, 148.02, 139.33, 139.10, 136.86, 
131.35, 130.42, 128.39, 127.38, 126.96, 125.74, 123.91, 122.67, 116.38, 115.81, 42.75. HRMS 
(ESI-TOF) m/z calcd for C19H13N2O2S [M-H]¯: 333.0698 Found: 333.0733. HPLC: retention 
time 13.76 min; purity >99%. 
N-(2-fluorophenethyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide 
(3.32): 
 
White solid (58%); 
1
H NMR (400 MHz, DMSO-d6) 11.79 (s, 1H, H
5
), 8.97 (m, 1H, H
15
), 
8.25 (s, 1H, H
3
), 7.88 (d, J = 7.9 Hz, 1H, H
9
), 7.53 (t, J = 7.8 Hz, 1H, H
7
), 7.42 (d, J = 8.2 Hz, 
1H, H
6
), 7.33 (m, 1H, H
20
), 7.26 (d, J = 7.4 Hz, 2H, H
8,22
), 7.14 (q, J = 8.6, 7.3 Hz, 2H, H
21,23
), 
3.50 (d, J = 6.8 Hz, 2H, H
16
), 2.90 (m, 2H, H
17
). 
13
C NMR (125 MHz, DMSO-d6) δ 160.62, 
158.07, 147.91, 139.50, 136.82, 131.28, 130.41, 128.46, 128.39, 125.95, 125.83, 125.46, 124.42, 
123.89, 122.72, 116.39, 115.84, 115.25, 115.08, 28.48. HRMS (ESI-TOF) m/z calcd for 
66 
 
C20H14FN2O2S [M-H]¯: 365.0760 Found: 365.0790. HPLC: retention time 13.78 min; purity 
>99%. 
Methyl 2-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)benzoate (3.33):  
 
 White solid (88%). 
1
H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H, ex, H
5
), 11.60 (s, 1H, 
ex, H
15
),8.35 (d, J = 8.4 Hz, 1H, H
9
), 8.26 (s, 1H, H
3
), 8.00 (d, J = 7.9 Hz, 1H, H
18
), 7.93 (d, J = 
7.9 Hz, 1H, H
21
), 7.68 (t, J = 8.0 Hz, 1H, H
7
), 7.55 (d, J = 7.7 Hz, 1H, H
20
), 7.44 (d, J = 8.3 Hz, 
1H, H
6
), 7.28 (t, J = 7.7 Hz, 2H, H
8,19
), 3.93 (s, 3H, H
23
). 
13
C NMR (100 MHz, DMSO-d6) δ 
167.69, 158.93, 157.74, 148.81, 138.98, 136.92, 133.95, 131.16, 130.58, 125.83, 123.87, 122.60, 
121.41, 118.25, 116.30, 115.52, 52.50. HRMS (ESI-TOF) m/z calcd for C20H13N2O4S [M-H]¯: 
377.0596. Found: 377.0595. HPLC: retention time 18.32 min; purity >99%. 
Methyl 3-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)benzoate  (3.35): 
 
 
White solid (55%). 
1
H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H, ex, H
5
), 10.75 (s, 1H, 
ex, H
15
), 8.66 (s, 1H, H
3
), 8.44 (s, 1H, H
17
), 8.11 (d, J = 8.3 Hz, 1H, H
19
), 7.93 (d, J = 7.9 Hz, 
1H, H
9
), 7.71 (d, J = 7.7 Hz, 1H, H
6
), 7.61 – 7.49 (m, 2H, H7,20), 7.45 (d, J = 8.3 Hz, 1H, H21), 
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7.27 (t, J = 7.6 Hz, 1H, H
8
), 3.88 (s, 3H, H
23
). 
13
C NMR (100 MHz, DMSO-d6) δ 166.01, 159.57, 
158.01, 148.77, 138.98, 136.97, 131.39, 130.63, 130.12, 129.28, 127.12, 124.45, 124.05, 122.70, 
120.57, 116.40, 115.70, 52.23. HRMS (ESI-TOF) m/z calcd for C20H13N2O4S [M-H]¯: 377.0596. 
Found: 377.0596. HPLC: retention time 17.34 min; purity >99%. 
4-oxo-N-(pyridin-2-yl)-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.37): 
 
 White solid (30%). 
1
H NMR (500 MHz, DMSO-d6) δ 11.84 (s, 1H, ex, H
5
), 11.29 (s, 1H, 
ex, H
15
), 8.79 (s, 1H, H
3
), 8.44 (d, J = 3.3 Hz, 1H, H
18
), 8.15 (d, J = 8.3 Hz, 1H, H
9
), 7.95 (d, J = 
7.9 Hz, 1H, H
21
), 7.87 (t, J = 7.8 Hz, 1H, H
20
), 7.57 (t, J = 7.8 Hz, 1H, H
7
), 7.45 (d, J = 8.2 Hz, 
1H, H
6
), 7.28 (t, J = 7.5 Hz, 1H, H
8
), 7.24 – 7.17 (m, 1H, H19). 13C NMR (125 MHz, DMSO-d6) 
δ 160.02, 157.94, 151.64, 148.94, 148.04, 138.76, 138.19, 137.01, 131.54, 130.64, 127.91, 
124.06, 122.64, 120.06, 116.35, 115.65, 114.92. HRMS (ESI-TOF) m/z calcd for C17H10N3O2S 
[M-H]¯: 320.0494. Found: 320.0498. HPLC: retention time 11.52 min; purity >99%. 
4-chloro-N-(pyridin-2-yl)thieno[3,2-c]quinoline-2-carboxamide (3.38): 
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White solid (23%). 
1
H NMR (400 MHz, DMSO-d6) δ 11.55 (s, 1H, ex, H
15
), 9.04 (s, 1H, 
H
3
), 8.45 (d, J = 4.5 Hz, 1H, H
18
), 8.35 (d, J = 8.0 Hz, 1H, H
9
), 8.19 (d, J = 8.3 Hz, 1H, H
6
), 8.10 
(d, J = 8.3 Hz, 1H, H
21
), 7.88 (t, J = 7.6 Hz, 2H, H
7,20
), 7.78 (t, J = 7.5 Hz, 1H, H
8
), 7.22 (dd, J = 
7.3, 4.8 Hz, 1H, H
19
). 
13
C NMR (100 MHz, DMSO-d6) δ 159.79, 151.59, 148.23, 148.10, 145.44, 
143.24, 141.03, 138.32, 131.78, 130.77, 128.94, 128.32, 126.16, 124.10, 122.53, 120.21, 114.78. 
HRMS (ESI-TOF) m/z calcd for C17H9ClN3OS [M-H]¯: 338.0155. Found: 338.0158. HPLC: 
retention time 18.97 min; purity >97%. 
4-oxo-N-(pyridin-3-yl)-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.39): 
 
Yield: 41% of a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 11.83 (s, 1H, ex, H
5
), 
10.74 (s, 1H, ex, H
15
), 8.95 (s, 1H, H
17
), 8.64 (s, 1H, H
3
), 8.34 (d, J = 4.6 Hz, 1H, H
19
), 8.19 (d, J 
= 8.3 Hz, 1H, H
9
), 7.94 (d, J = 7.9 Hz, 1H, H
21
), 7.56 (t, J = 7.7 Hz, 1H, H
7
), 7.49 – 7.38 (m, 2H, 
H
6,20
), 7.28 (t, J = 7.5 Hz, 1H, H
8
). 
13
C NMR (125 MHz, DMSO-d6) δ 159.78, 158.02, 148.85, 
144.88, 141.75, 138.66, 137.01, 135.28, 131.37, 130.74, 127.31, 127.21, 124.10, 123.68, 122.76, 
116.45, 115.69. HRMS (ESI-TOF) m/z calcd for C17H10N3O2S [M-H]¯: 320.0494. Found: 
320.0502. HPLC: retention time 10.97 min; purity >99%. 
 
Representative procedures for the synthesis of 3.24 and 3.26 
 
N-(2-aminoethyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.24): 
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To a stirred suspension of tert-butyl (2-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-
carboxamido)ethyl)carbamate (3.23) (0.03g, 0.075 mmol) in 5 mL of CH2Cl2 was added 4M HCl 
in dioxane (500 L) and the mixture was stirred for 8h at ambient temperature. The precipitated 
solid was filtered, washed with Et2O and dried under vacuum to yield the title compound as a 
white solid (0.024 g, 96%). 
1
H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H, ex, H
5
), 9.08 (s, 1H, 
ex, H
15
), 8.35 (s, 1H, H
3
), 7.90 (d, J = 8.0 Hz, 3H, 2 ex, H
9,18
), 7.54 (t, J = 7.9 Hz, 1H, H
7
), 7.44 
(d, J = 8.4 Hz, 1H, H
6
), 7.26 (t, J = 7.8 Hz, 1H, H
8
), 3.65 – 3.41 (m, 2H, H16), 3.00 (t, J = 6.6 Hz, 
2H, H
17
). 
13
C NMR (125 MHz, DMSO-d6) δ 161.18, 157.93, 147.95, 138.85, 136.84, 131.21, 
130.40, 126.18, 123.83, 122.61, 116.34, 115.71, 38.45, 37.13. HRMS (ESI-TOF) m/z calcd for 
C14H12N3O2S [M-H]¯: 286.0650. Found: 286.0644. HPLC: retention time 8.46 min; purity 
>99%. 
N-(3-aminopropyl)-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide (3.26): 
 
 Yield: 92% of a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 11.82(s, 1H, ex, H
5
), 9.03 
(s, 1H, ex, H
15
), 8.33 (s, 1H, H
3
), 8.06 – 7.70 (d, J = 7.9 Hz, 3H, 2 ex, H9,18), 7.53 (t, J = 7.7 Hz, 
1H, H
7
), 7.44 (d, J = 8.3 Hz, 1H, H
6
), 7.25 (t, J = 7.5 Hz, 1H, H
8
), 3.43 – 3.33 (m, 2H, H16), 2.86 
(t, J = 6.7 Hz, 2H, H
18
), 1.90 – 1.76 (m, 2H, H17). 13C NMR (125 MHz, DMSO-d6) δ 160.83, 
157.97, 147.91, 139.23, 136.82, 131.27, 130.39, 125.69, 123.84, 122.64, 116.36, 115.76, 36.45, 
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36.06, 27.20. HRMS (ESI-TOF) m/z calcd for C15H14N3O2S [M-H]¯: 300.0807. Found: 
300.0812. HPLC: retention time 8.71 min; purity >99%. 
Representative procedures for the synthesis of 3.34 and 3.36 
 
2-(4-Oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)benzoic acid (3.34):  
 
 
 To a stirred suspension of methyl 2-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-
carboxamido)benzoate (3.33) (0.025g, 0.066 mmol) in 5 mL of MeOH was added 1 N NaOH (1 
mL) and the mixture was stirred for 30 min at ambient temperature. It was then quenched with 
10% HCl. The precipitated solid was filtered, washed successively with H2O and Et2O and dried 
under vacuum to yield the title compound as a white solid (0.022 g, 92%). 
1
H NMR (400 MHz, 
DMSO-d6) δ 13.87 (s, 1H, ex, H
23
), 12.48 (s, 1H, ex, H
5
), 11.91 (s, 1H, ex, H
15
), 8.51 (d, J = 8.3 
Hz, 1H, H
9
), 8.19 (s, 1H, H
3
), 8.06 (d, J = 7.8 Hz, 1H, H
18
), 7.95 (d, J = 7.9 Hz, 1H, H
21
), 7.66 (t, 
J = 8.0 Hz, 1H, H
7
), 7.57 (t, J = 7.9 Hz, 1H, H
20
), 7.45 (d, J = 8.3 Hz, 1H, H
6
), 7.32 – 7.19 (m, 
2H, H
8,19
). 
13
C NMR (125 MHz, DMSO-d6) δ 169.47, 158.52, 157.44, 148.48, 139.75, 138.71, 
136.64, 133.74, 130.86, 130.36, 125.25, 123.62, 123.03, 122.34, 119.88, 117.10, 116.04, 115.24. 
HRMS (ESI-TOF) m/z calcd for C19H11N2O4S [M-H]¯: 363.0440. Found: 363.0443. HPLC: 
retention time 17.36 min; purity >99%. 
3-(4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamido)benzoic acid (3.36):  
71 
 
 
 
 
 
 
Yield: 71% of a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 13.04 (s, 1H, ex, H
23
), 
11.86 (s, 1H, ex, H
5
), 10.74 (s, 1H, ex, H
15
), 8.67 (s, 1H, H
3
), 8.42 (s, 1H, H
17
), 8.08 (d, J = 8.1 
Hz, 1H, H
19
), 7.95 (d, J = 7.9 Hz, 1H, H
9
), 7.70 (d, J = 7.7 Hz, 1H, H
6
), 7.61 – 7.41 (m, 3H, 
H
7,20,21
), 7.28 (t, J = 7.6 Hz, 1H, H
8
). 
13
C NMR (125 MHz, DMSO-d6) δ 167.05, 159.52, 158.00, 
148.71, 139.08, 138.80, 136.96, 131.36, 130.61, 129.03, 127.05, 124.67, 124.08, 122.69, 120.86, 
116.39, 115.70. HRMS (ESI-TOF) m/z calcd for C19H13N2O4S [M+H]
+
: 365.0596. Found: 
365.0591. HPLC: retention time 15.41 min; purity >99%. 
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CHAPTER 5: ATTEMPTED BIOLOGICAL EVALUATIONS OF THE VIRTUAL 
SCREENING HITS USING FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) 
BASED ASSAY 
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5.1. Introduction 
  
5.1.1 FRET based kinase assay 
 
Protein kinases act as phosphoryl transferases, which phosphorylate serine, threonine or 
tyrosine residues of a substrate by transferring the-phosphate group of an ATP and in turn 
convert ATP to ADP. There are several methods to assay this kinase activity. These methods 
involve the quantification of this phosphoryl transfer reaction by detecting the phosphorylated 
product or the change in the ratio of ATP to ADP. The detection can be done in following ways: 
a) Radiometric assays 
b) Fluorometric assay 
c) Enzyme-linked immunosorbent assay (ELISA) 
d) Luminescence assay 
e) Mobility shift assay 
One of the simplest methods is the fluorometric method, which uses non-radioactive material. So 
it has less liability in terms of handling or waste disposal. One of these methods uses 
fluorescence resonance energy transfer (FRET) between a donor (coumarin) and an acceptor 
(fluorescein). The commercially available assays include Invitrogen’s Z'-Lyte™ assay, which 
can be used in any lab set-up to reliably screen potential kinase inhibitors in a two hour reaction 
at room temperature. The Z'-Lyte™ assay uses synthetic FRET-peptide substrates labeled with a 
donor (i.e., coumarin) and acceptor (i.e., fluorescein). The reaction occurs in two stages. 
Primarily in a kinase reaction, the kinase transfers the -phosphate of the ATP to a tyrosine, 
serine or threonine, but in presence of kinase inhibitor this phosphorylation reaction diminishes. 
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In a secondary reaction, with the addition of the development reagent, the development buffer 
quenches the kinase reaction and compared to the phosphorylated state, the non-phosphorylated 
state, gets cleaved faster by a protease, which disrupts the FRET pair. Thus produces less 
fluorescence. Better the inhibitor potential lower would be the number of FRET transfer. The 
FRET is expressed by calculating the emission ratio, which is defined as, 
Emission ratio = coumarin emission/fluorescein emission. 
 The % phosphorylation is defined as, 
 
% Phosphorylation = 100 X (1-(((emission ratio X F100%)/((C0% - C100%) + (emission ratio X            
(F100% - F0%))))) 
  
Whereas the % inhibition is given as, 
% Inhibition = 100 - % phosphorylation 
 
5.1.2. Poor solubility issues 
 
 In general, kinase inhibitors are known to be insoluble compounds, because of the 
presence of number of hetero atoms or heterocycles in the molecules. Several groups have 
worked on solving the solubility problems in drug molecules, using different formulations 
containing mixtures of alcohols and emulsifiers. Cremophor EL is a non-ionic solubilizer and 
emulsifier often used for various poorly-water soluble drugs, including the anticancer agent 
paclitaxel (Taxol),
103
 cyclosporine A
104
 and 9-tetrahydrocannabinol.105 
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5.2. Methods 
 
5.2.1. General 
 
Staurosporine, R-roscovitine standards were purchased from Enzo Life Sciences 
(www.enzolifesciences.com). CDK5/p25, CDK2/A, Z'-Lyte™ kinase assay kit-Ser/Thr 12 
Peptide were bought from Invitrogen™, Life Technologies.106 Cremophore EL was purchased 
from Sigma-Aldrich Corporation (www.sigmaaldrich.com). Perkin Elmer EnVision® multilabel  
Plate reader using Photometric 405 Excitation Filter  and two Emission Filters (Photometric 450 
and  Fura2 510) was used to read 384-well black NBS™ coated plates from Corning Inc. 
(www.corning.com). 
5.2.2. Compound stock solution preparation 
 
 All the compounds were dissolved in a mixture containing 1:1:18 (v/v/v) mixture of 
water with 10% DMSO : EtOH : cremophor EL at 1 mM concentration. 100 M was the highest 
concentration, we screened for any compounds. Since we had to prepare 4X concentration, the 
400 M samples were prepared by diluting the stock solution with the same solvent mixture. We 
used the blank solvent mixture to do a baseline correction of the fluorescence reading. 
5.2.3 CDK5/p25 and CDK2/A kinase assay 
  
The method used is described as follows 
1. 2.5 μL – 4X Test Compound  
2. 5 μL – 2X Peptide/ specific Kinase Mixture  
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3. 2.5 μL – 4X ATP Solution  
4. 30-second plate shake  
5. 60-minute Kinase Reaction incubation at room temperature  
6. 5 μL – Development Reagent Solution  
7. 30-second plate shake  
8. 60-minute Development Reaction incubation at room temperature  
9. Read on fluorescence plate reader and analyzed the data  
10. The EC50/IC50 values were generated using GraphPad Prism.
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5.3. Results and Discussions 
 
 Both staurosporine (5.1) and R-roscovitine (2.1) were used as the standards and analyzed 
first in the CDK5/p25 and CDK2/A assays. The structures of the staurosporine and R- 
roscovitine are given in Figure 5.1. 
 
Figure 5.1. Structures of staurosporine and R-roscovitine 
 
 The determined IC50 values for staurosporine and R-roscovitine are given as follows: 
Staurosporine CDK5/p25 IC50 = 39 nM; CDK2/A IC50 = 7.7 nM 
R-roscovitine CDK5/p25 IC50 = 1.34 M; CDK2/A IC50 = 1.29 M 
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The staurosporine IC50 in Z′-Lyte assay was reported as CDK5/p25 IC50 = 9.7 nM; 
CDK2/A IC50 = 5.88 nM in the Invitrogen Z'-Lyte manual.
108
 We found out that the IC50 values 
obtained from the Z′-Lyte assay for staurosporine showed nanomolar potencies in both the 
kinases as reported. But the micromolar IC50 values of R- roscovitine in our assay deviated a lot 
from the sub-micromolar numbers reported earlier.
16
 The IC50 curves for staurosporine and R-
roscovitine are shown in Figure 5.2. 
 
 
 
  
 
 
 
 
 
Figure 5.2. Z'-Lyte IC50 curves of staurosporine and R-roscovitne in CDK5/p25 and CDK2/A 
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We evaluated the selected hits from the virtual screening (Chapter 2) in our Z'-Lyte assay 
condition. A highest concentration of 100 M was used for the compounds in the Z'-Lyte assays. 
We observed that the compounds did not produce reasonable IC50 curves in either CDK5/p25 or 
CDK2/A. Also the % inhibition did not reach to 50% mark for most of the compounds to 
produce meaningful IC50 values.  
Following are the IC50 curves of 2.5 as described in Figure 5.3. 
 
 
 
 
Figure 5.3. IC50 curves for 2.5 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.6 are given below in Figure 5.4 
 
 
 
 
 
Figure 5.4. IC50 curves for 2.6 in CDK5/p25 and CDK2/A 
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The IC50 curves of 2.7 are given below in Figure 5.5 
 
 
 
 
 
Figure 5.5. IC50 curves for 2.7 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.8 are given below in Figure 5.6 
 
 
 
 
 
Figure 5.6. IC50 curves for 2.8 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.9 are given below in Figure 5.7 
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Figure 5.7. IC50 curves for 2.9 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.10 are given below in Figure 5.8 
 
 
 
 
 
 
Figure 5.8. IC50 curves for 2.10 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.11 are given below in Figure 5.9 
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Figure 5.9. IC50 curves for 2.11 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.12 are given below in Figure 5.10 
 
 
 
 
 
Figure 5.10. IC50 curves for 2.12 in CDK5/p25 and CDK2/A 
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The IC50 curves of 2.13 are given below in Figure 5.11 
 
 
 
 
 
 
Figure 5.11. IC50 curves for 2.13 in CDK5/p25 and CDK2/A 
 
The IC50 curves of 2.14 are given below in Figure 5.12 
 
 
 
 
 
Figure 5.12. IC50 curves for 2.14 in CDK5/p25 and CDK2/A 
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5.4. Conclusions 
 
 All the virtual screening compounds tested in Z′-Lyte assay did not generate reasonable 
IC50 curves in either CDK5/p25 or CDK2/A. The % inhibitions of some of the compounds did 
not reach the 50% mark for us to calculate a meaningful IC50 values. There could be a number of 
reasons for which we did not get 50% inhibition. Primarily, we could speculate about the poor 
solubility of the compounds. We have already encountered the poor solubility issues and used a 
1:1:18 (v/v/v) mixture of water with 10% DMSO: EtOH: cremophor EL to dissolve the 
compounds at 1 mM concentration. The highest concentration tested was 100 M, for which we 
had to prepare required 400 M concentration (4X). But during the kinase reactions, compounds 
get diluted with the reaction buffer. The dilution with aqueous buffer may cause precipitation. 
Consequently, it will increase the absorbance reading and in turn the % inhibition number will go 
down. The poor performance of the assay was also reflected on the % inhibition value of the R-
roscovitine. We observed that in the Z'-Lyte assay, the IC50 value of R-roscovitine was 10 fold 
less potent than the values reported in the literature. So hypothetically, if the tested compound 
would have a real IC50 value of 20 M, in this assay, it will generate a 10 fold less potent number 
of 200 M. And since the highest concentration we tested was 100 M, we won’t be able to get a 
meaningful IC50 curve for the hypothetical compound. All these data forced us to look for 
alternate assay methods to assay these compounds. 
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CHAPTER 6: BIOLOGICAL EVALUATION USING RADIOMETRIC ASSAYS AND SAR 
ANALYSIS 
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6.1. Introduction 
  
 Protein kinases act as phosphoryl transferases, which phosphorylate serine, threonine or 
tyrosine residues of a substrate by transferring the-phosphate group of the ATP and in turn 
convert ATP to ADP. Since our attempted biological evaluation in FRET based assay failed, we 
returned our focus on a robust assay method. Among many kinase assays, radiometric methods 
are the most reliable method of detecting kinase reactions.
109
 In the P81 filter binding 
radiometric method, the homogeneous kinase reaction is performed in the presence of ATP, 
which is spiked with [-33P] ATP and allowed to bind to the protein substrate. The incorporation 
of this radio-labeled phosphate to the filter bound substrate is then assayed after a series of 
binding and washing steps. The reaction data is then background subtracted by subtracting the 
signal obtained from control kinase reactions flooded with EDTA, which kills the kinase activity. 
The average signal from those EDTA wells is therefore set to kinase 0% activity. The average 
signal of DMSO only wells is set to 100% activity. Test compound data is then expressed within 
that signal range as percent residual kinase activity.  Then inhibition is measured using the 
following formula, 
% Inhibition = 100 - % activity. 
 
The target was to find active compounds for CDK5/p25. Compounds were also needed to 
be screened for selectivity against CDK2/E. The reason CDK2/E was chosen instead of 
CDK2/A, because cyclin E expression was identified in the post neuronal cytoplasm, where 
CDK5 plays an important part in AD pathogenesis.
110
  The ATP binding rate for any particular 
kinase is half maximal at Michaelis-Menten constant (Km) concentration. It is a true comparison 
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between any numbers of kinases if the assays are performed at ATP Km values, because all 
kinases are at half maximal rate.  
For ATP competitive inhibition assay, the nature of the double reciprocal (Lineweaver-
Burk) plot can express whether it is a competitive or non-competitive inhibition. For competitive 
binding the lines are going to merge on Y-axis. On the other hand, it is going to be a non-
competitive binding, if the lines converge on X-axis. The Michaelis-Menten equation of 
reversible enzyme kinetics for mixed inhibitor can be represented as, 
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Where  is velocity, [S] is substrate (ATP) concentration, [I] is inhibitor concentration, Ki is 
inhibitor affinity for enzyme, and Ki' is inhibitor affinity for enzyme/ATP complex.   
The Lineweaver-Burk plot is a graphical plot of 1/ –vs– 1/[S]. 
 Finally a panel of serine/threonine and tyrosine kinases is selected either on the basis of 
their existence in the CDK family or for their tau phosphorylation pathways.
111
  
 
6.2. Methods 
All the assays were performed at Reaction Biology Corp.
112
 according to their standard 
procedure. The customer protocols are described below. 
6.2.1. Radiometric CDK5/p25 and CDK2/E kinase assays 
 
The phosphorylation of histone H1by ATP was conducted in a base buffer containing 20 
mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM 
Na3VO4, 2 mM DTT, 1% DMSO at Km ATP concentration (spiked with [-
33
P] ATP).The 
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reactions were conducted in duplicate and initiated by the addition of hCDK5/p25 or hCDK2/E 
and the compounds dissolved in 4% DMSO solution. The reaction was incubated at room 
temperature for 120 min after which it was stopped by adding EDTA and filtered through P81 
ion exchange paper. It was then washed with 0.75% phosphoric acid, which removed any free 
33
P signal. The 
33
P that was transferred onto the substrate however remained on the filter with the 
bound substrate. The signal intensities were recorded and the raw image data was converted into 
numbers.  The reaction data was then background subtracted by subtracting the signal obtained 
from control kinase reactions flooded with EDTA, which killed the kinase activity. The average 
signal from those EDTA wells was considered to be the kinase 0% activity. The average signal 
of DMSO only wells was set to 100% activity. Test compound data was expressed between the 
0-100% signal ranges as percent residual kinase activity.  The IC50 for each compound was 
determined from dose-response curves ran at ATP (Km) concentrations of 30 M for CDK5/p25 
and 65 M for CDK2/E and at least two independent experiments were performed to generate 
the average numbers. Staurosporine was used as positive controls for the assays. 
6.2.2. ATP competitive binding assay 
 
ATP competitive binding assay was performed in the same manner as the radiometric 
filtration assay with different ATP concentrations of 10, 30, 75, 150 and 300 M with 
hCDK5/p25. A 10 point IC50 curve was determined. The Ki was calculated using GraphPad 
Prism.
107
  
6.2.3. Selectivity assay 
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The selectivity assays were performed the same way as the radiometric filter binding 
assay using full length human kinases with the appropriate co-factors as mentioned in the 
selected panel of kinases. All the assays were performed at ATP Km concentrations and 20 M 
compound concentrations. At least two independent experiments were performed to generate the 
average % activity. 
6.3. Results and Discussions 
 
The identified nine compounds from the virtual screening were tested in the -33P ATP 
filter binding assay using full length hCDK5/p25 and hCDK2/E at Reaction Biology Corp.
112, 113
 
The % inhibitions at 50 M concentration were determined at 10 M ATP and the compounds 
with greater than 50% inhibition were re-screened (at ATP Km concentrations) for relevant % 
inhibitions or IC50 (generated from the dose-response curves). The intermediate carboxylic acid 
(2.14) was also tested and shown to be active at 50 M concentrations. The in-vitro potencies of 
the selected compounds are reported in Table 6.1. 
It was observed that among the tested compounds 2.5, 2.7, 2.8 were equipotent in both 
the enzymes, whereas 2.9 and 2.12 showed preferential activity towards CDK2/E. The success of 
the computational model was established by CDK5/p25 selectivity of compounds 2.6, 2.10, 2.11 
and 2.13 making a 40% positive turnover rate for the model. The intermediate 2.14 also showed 
preferential activity towards CDK5/p25. We used 2.1 and 2.4 as the standards for the assay 
validation and found that both the compounds showed sub-micromolar activities for CDK5/p25 
as reported earlier,
16, 28
 but showed selectivity towards CDK2/E. 
 Compound 2.10 showed reasonably good potency for CDK5/p25 (IC50=7 M) and four 
fold selectivity over CDK2/E (IC50=25 M) with a calculated ligand efficiency
114
 (LE) of 0.3. 
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The carboxylic acid (2.14) also showed moderate activity in CDK5/p25 (IC50=52 M) and good 
selectivity over CDK2/E (showed 14% inhibition @ 50 M concentration).  
 
Table 6.1. In-vitro CDK5/p25 and CDK2/E assay 
a 
Assays were performed in duplicate @ 10 M ATP and 50 M compound concentrations 
b
 Assays were performed @ ATP (Km) concentrations of 30 M for CDK5/p25 and 65 M for 
CDK2/E and at least two independent experiments were performed to generate the average 
numbers 
c
 % inhibitions were generated @ 50 M compound and ATP Km concentrations 
 
The selectivity of 2.10 can be explained by its docking pose in CDK5/p25 showing H-
bonding interactions with Asp86 and Asn144 (Figure 6.1 A), whereas in CDK2, the only 
interaction existed was with water a molecule (represented by black dotted line in Figure 6.1 B). 
In CDK2 two other residues (Thr14 and Asp145) were at 3.5 Å distances (represented by red 
dotted line in Figure 6.1 B), which were only viable for very weak H-bonding with 2.14. The 
selectivity of the carboxylic acid (2.14) can be explained by its H-bonding interactions with 
Cys83 and Lys33 in CDK5/p25 (Figure 6.1 C) compared to the only interactions with Leu83 in 
case for CDK2 (Figure 5.1 D). The diagrams in Figure 5.1 were generated by Pymol.
36
 
Compound 
# 
CDK5/p25 
% inhibition
a
 
@ 50 M  
CDK2/E  
% inhibition
a
  
@ 50 M 
CDK5/p25 
IC50 (M)
b
 
CDK2/E 
IC50 (M)
b
 
2.5 20.0 24.2   
2.6 43.1 32.3   
2.7 23.6 29.9   
2.8 12.7 14.8   
2.9 25.2 38.7   
2.10 88.2 77.0 7.02 25.8 
2.11 17.2 8.0   
2.12 48.3 58.2 107 81.7 
2.13 14.7 5.3   
2.14 64.8 23.5 52.1 14.5% inh
c
 
2.1   0.188 0.028 
2.4   0.655 0.417 
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Figure 6.1. H-bonding interactions of 2.10 and 2.14 with CDK5/p25 (A, C) and CDK2 (B, D) 
 
Black dotted lines represent H-bonding interactions; Red dotted lines represent measured 
distances showing probable very weak H-bonding within 3.5 Å. 
 
The identification of a novel thieno[3,2-c]quinolin-4(5H)-one derivative (2.10) with 
LE=0.3 from virtual screening and an intermediate (2.14) with moderate activity in the same 
series, led us to choose 2.10 as the lead molecule to proceed with mechanistic evaluation and 
further SAR development. In an ATP competitive binding assay, performed at Reaction Biology 
Corp.,
112
 2.10 showed non-competitive inhibition as represented by unchanged IC50 values with 
the increase in ATP concentrations (Figure 6.2 A). The convergence of all the lines on X-axis of 
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the double-reciprocal (Lineweaver-Burke) plot in Figure 6.2 B, reiterated the non-competitive 
binding as well.  
 
 
 
Figure 6.2.  IC50 curves (A) and Lineweaver-Burk Plot (B) of 2.10 in CDK5/p25 at different 
ATP concentrations 
 
 
 
 
Figure 6.3.  IC50 curves (A) and Lineweaver-Burk Plot (B) of 2.14 in CDK5/p25 at different 
ATP concentrations 
 
On the contrary when we tested the carboxylic acid, (2.14) we observed the apparent Km 
increased with the increase in inhibitor concentration and all lines were converged on the Y-axis 
in the double-reciprocal plot (Figure 6.3 B), suggesting that the compound is competitive with 
respect to ATP against CDK5/p25. In the plot of % enzyme activities at each ATP concentrations 
-9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
10 uM ATP
30 uM ATP
75 uM ATP
150 uM ATP
300 uM ATP
HillSlope
EC50
10 uM ATP 
-0.9769
5.444e-006
30 uM ATP
-1.252
8.229e-006
75 uM ATP
-1.046
5.853e-006
150 uM ATP
-1.589
7.913e-006
300 uM ATP
-1.827
8.127e-006
Log [Compound] (M)
%
 A
c
ti
v
it
y
A
-9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
10 uM ATP
30 uM ATP
75 uM ATP
150 uM ATP
300 uM ATP
HillSlope
EC50
10 uM ATP 
-0.8630
4.806e-005
30 uM ATP
-0.6438
8.384e-005
75 uM ATP
-0.7459
0.0002765
150 uM ATP
-0.2506
0.02635
300 uM ATP
Log [Compound] (M)
%
 A
c
ti
v
it
y
A
-0.025 0.000 0.025 0.050 0.075 0.100
100
200
300
400
DMSO
26.7 uM
80 uM
Y-intercept when X=0.0
X-intercept when Y=0.0
1/slope
DMSO
45.86 ± 0.1844
-0.08999
0.001962
26.7 uM
47.70 ± 2.929
-0.03756
0.0007875
80 uM
44.44 ± 1.629
-0.01690
0.0003802
1/ATP (1/uM)
1
/V
e
lo
c
it
y
B
92 
 
-vs- compound concentration, the IC50 values were shifted higher with ATP concentration 
increase, as expected for competitive inhibitors (Figure 6.3 A). It was observed that at higher 
concentrations of ATP, the solubility of the compound falls off. 
Non-competitive inhibition of (2.10) can be explained by a speculative hypothesis that in 
its protonated form the 2-pyridine amide was interacting with the Asp86 and pushed the rest of 
the molecule deep into the pocket to H-bond with Asn144 (Figure 6.1 A). On the other hand the 
carboxylic acid (2.14) failed to reach deep into the pocket and consequently showed competitive 
inhibition (Figure 6.1 C). To further test this hypothesis we synthesized several 2- (ortho-) 
substituted analogs exploiting this deep pocket interaction and we were pleased to observe the 
similar non-competitive inhibitions for these SAR compounds.  
The primary goal of the SAR was to improve the activity of CDK5/p25 and selectivity 
against CDK2/E. We also synthesized several analogs exploiting the probable deep pocket H-
bonding interactions to understand the ATP non-competitive binding of 2.10. 
In the SAR effort we focused our emphasis mainly on the C-ring substitutions as shown 
in Table 3.3. We utilized convergent analog synthesis to systematically explore different 
substitutions like esters, aliphatic amides, solubilizing groups, aromatic and hetero-aromatic 
amides as described in Chapter 3. 
The ester (3.15) and the simple unsubstituted aliphatic amide (3.16) showed no 
significant activities either in CDK5/p25 or in CDK2/E assays. The same activity trend persisted 
as we screened more substituted aliphatic amides (3.17-3.20) or amides with water soluble 
groups (3.21-3.26). But the trend suddenly showed improvement as we started exploring 
aromatic amides (3.27-3.36). However, we have observed that the over-extension of the 
aromatics with linkers caused disruption of the aromatic stacking for 3.31 and 3.32, which 
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resulted in no activity. It can be concluded that CDK5/p25 activity requires aromatic interactions 
of the amides. By Comparing 3.28 and 3.30, we observed a drastic increase in CDK2/E 
selectivity for 3.30 from 5 fold to a greater than 10 fold, while slightly improving CDK5/p25 
activity (IC50 = 3.6 M). This can be explained by extra H-bonding of the ortho- F group in 3.30 
as we observed previously with protonated 2-pyridyl of 2.10. We prepared analogs 3.33 and 3.34 
by exploiting this H-bonding interaction of the ortho- groups and we observed incresed 
selectivity for both compounds. 3.34 showed the best selectivity profile in the series (at least >13 
fold selectivity) and a low micromolar activity in CDK5/p25 (IC50 = 4.3 M). Both 2-pyridyl 
compounds (3.37 and 3.38) showed low micromolar activities in CDK5/p25 (for 3.37 IC50 = 4.3 
M; for 3.38 IC50 = 3.8 M), with highly improved selectivty for the by-product thieno[3,2-
c]quinoline derivative (3.38). The selectivity trend did not go beyond the ortho- substitutions, as 
observed for the 3- (meta-) substituted compounds (3.29, 3.35, 3.36 and 3.39) did not provide 
good selectivities. The in-vitro data of CDK5/p25 and CDK2/E assays for all the SAR 
compounds are described in Table 6.3. 
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Table 6.3. In-vitro CDK5/p25 and CDK2/E assay of SAR compounds 
Compound 
CDK5/p25 inhibition 
@50Ma 
CDK5/p25 
IC50 (M)
a
 
CDK2/E inhibition 
@50Ma 
CDK2/E 
IC50 (M)
a
 
3.15  58.1 7.9% - 
3.16 29.0% - 21.8% - 
3.17 No inhibition - 12% - 
3.18 No inhibition - 10% - 
3.19 No inhibition - No inhibition - 
3.20 No inhibition - No inhibition - 
3.21 24.9% - 15.9% - 
3.22 16.6% - 8.8% - 
3.23 23.3% - 12.3% - 
3.24 15.3% - 4.9% - 
3.25 13.1% - 6.5% - 
3.26 12.8% - 3.7% - 
3.27  29.2  35.3 
3.28  5.2  27.4 
3.29  15.6  53.8 
3.30  3.6  35.4 
3.31 No inhibition - No inhibition - 
3.32 No inhibition - No inhibition - 
3.33  3.0  25.5 
3.34  4.3 No inhibition  
3.35  1.6  6.3 
3.36 27.4% - No inhibition - 
3.37  4.3  9.9 
3.38  3.8 21.8% - 
3.39  10.6 36.7% - 
a
 Assays were performed @ ATP (Km) concentrations of 30 M for CDK5/p25 and 65 M for 
CDK2/E and at least two independent experiments were performed to generate the average 
numbers 
 
From the above SAR we have identified three compounds (3.30, 3.34 and 3.38) with low 
micromolar potencies and improved selectivities for further evaluation in ATP competitive 
binding at Reaction Biology Corp.
112
  
For 3.30 we observed that all the lines converged on the X-axis in the double-reciprocal 
plot (Figure 6.4 B), suggesting that the compound is noncompetitive with respect to ATP against 
CDK5/p25. When % enzyme activities of slopes relative to DMSO control at each ATP 
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concentration are plotted against compound concentration and IC50 curves were drawn, the IC50 
values were unchanged significantly when ATP concentration was increased, as expected for 
noncompetitive inhibitors (Figure 6.4 A).  
 
Figure 6.4.  IC50 curves (A) and Lineweaver-Burk Plot (B) of 3.30 in CDK5/p25 at different 
ATP concentrations 
 
 
 
 
Figure 6.5.  IC50 curves (A) and Lineweaver-Burk Plot (B) of 3.34 in CDK5/p25 at different 
ATP concentrations 
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compound concentration and IC50 curves were drawn, the IC50 values were unchanged 
significantly when ATP concentration was increased, as expected for noncompetitive inhibitors 
(Figure 6.5 A). Also we observed that all the lines converged on the X-axis in the double-
reciprocal plot (Figure 6.5 B), suggesting that the compound is noncompetitive with respect to 
ATP against CDK5/p25.  
For 3.38 the ATP competitive binding assay revealed that when % enzyme activities of 
slopes relative to DMSO control at each ATP concentration are plotted against compound 
concentration and draw IC50 curves, the IC50 values were unchanged significantly when ATP 
concentration was increased, as expected for noncompetitive inhibitors (Figure 6.6 A). Also we 
observed that all the lines converged on the X-axis in the double-reciprocal plot (Figure 6.6 B), 
suggesting that the compound is noncompetitive with respect to ATP against CDK5/p25. 
 
Figure 6.6.  IC50 curves (A) and Lineweaver-Burk Plot (B) of 3.38 in CDK5/p25 at different 
ATP concentrations 
 
 All three selected compounds showed non-competitive ATP binding, which proved our 
hypotheses of deep pocket interaction to produce non-competitive inhibition. 
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Since we are targeting CDK5/p25 inhibitors for AD, we calculated the predicted 
properties of these three identified compounds to profile their brain permeability, physico-
chemical properties and metabolic liabilities using QikProp (Table 6.4).
80
. We found that all 
three compounds have good BBB permeabilities, low metabolic liabilities and good physico-
chemical properties as predicted in-silico. 
Table 6.4. Calculated properties of compounds 3.30, 3.34 and 3.38 
 
 
 
Finally, we screened these three most potent, selective and non-ATP competitive 
compounds for selectivity in several serine/threonine and tyrosine kinases (Table 6.4). The % 
inhibitions were determined at 20 M of compound concentrations and at ATP Km 
concentrations of the recombinant human kinases. At least two independent experiments were 
performed to generate the average numbers 
In general the three CDK5/p25 inhibitors showed selectivity over the cell cycle kinases, 
such as  CDK1/B,CDK2/A, CDK2/E, CDK4/D1, CDK6/D1 and WEE1 (nuclear kinase). 
However, 3.30 and 3.34 showed some activity at few other kinases as described in Table 6.5. 
The best selectivity profile was observed for 3.38, which showed only off-target activity in 
HER2 (Human Epidermal Growth Factor Receptor 2) among the tested kinases. 
 
 
 
 
Compound 
# 
Molecular 
weight 
LogP 
(o/w) 
LogBB # Metab 
3.30 356.346 3.202 -0.588 2 
3.34 364.375 2.204 -1.655 3 
3.38 339.798 3.79 -0.182 3 
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Table 6.5. Selectivity profile (% inhibition at 20 M)a of 3.30, 3.34 and 3.38 
Kinases 3.30 3.34 3.38 
ATP Km 
(M) 
CDK1/B 56 No inhibition 35 5 
CDK2/A 58 50 45 10 
CDK2/E 27 5 6 65 
CDK4/D1 8 No inhibition No inhibition 90 
CDK6/D1 26 No inhibition No inhibition 30 
CK1a1 22 41 19 10 
DYRK1/DYRK1A 12 23 4 30 
ERBB2/HER2 79 82 77 50 
GSK3 65 79 22 30 
GSK3 53 81 41 5 
KDR/VEGFR2 95 88 44 30 
PKA 3 89 No inhibition 20 
PKC 8 No inhibition 1 10 
PKC 32 7 4 35 
WEE1 11 No inhibition 2 50 
a
 Assays were performed @ ATP (Km) concentrations and at least two independent experiments 
were performed to generate the average numbers 
 
 
6.4. Conclusions 
 
In summary, the identified hits from the virtual screening strategy were evaluated in 
radiometric filter binding assays in hCDK5/p25 and hCDK2/E. A novel thieno[3,2-c]quinolin-
4(5H)-one lead (2.10) with 0.3 LE was identified by its modest potency (CDK5/p25 IC50 = 7.02 
M) and selectivity (4 fold) over CDK2/E. Mechanistic evaluation revealed the nature of the 
ATP non-competitive inhibition of 2.10. This led us to develop a synthetic strategy to evaluate 
further SAR compounds. We developed a diverse SAR by using convergent analog synthesis 
strategy to achieve substituted C-ring analogs of thieno[3,2-c]quinolin-4(5H)-one (3.1). By 
analyzing the docked pose of 2.10, we postulated two working hypotheses of ortho- substitution 
H-boding to produce selectivity and deep pocket interaction to generate ATP non-competitive 
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binding interaction. Subsequently, we identified three low micromolar ATP non-competitive 
CDK5/p25 inhibitors 3.30, 3.34 and 3.38 with much greater CDK2/E selectivity. We screened 
the three identified compounds for broader selectivity in a panel of kinases. We observed all 
three compounds showed good selectivity over cell cycle kinases and among them 3.38 showed 
better overall selectivity across the selected panel with an off-target activity in HER2. This 
represents a new series of compounds with ATP non-competitive CDK5/p25 inhibitions. The 
results of this study may prove useful in the future optimization of this novel series of CDK5/p25 
inhibitors. 
Biochemically, there are clear indications about the involvement of CDK5/p25 complex 
in the hyperphosphorylation of tau leading to NFT formation leading to Alzheimer’s disease.7-9 
The known kinase inhibitors selected to-date for evaluation in AD, such as R-(-) roscovitine, 
flavopiridol, indirubin-3′-oxime and kenpaullone showed lack of selectivity and are termed as 
pan-kinase inhibitors.
25
 The three selective and non ATP-competitive CDK5/p25 inhibitors 
(3.30, 3.34 and 3.38) identified from the dissertation research showed not only low micromolar 
activity in CDK5/p25, but also good selectivity against all the cell cycle kinases. Additionally, 
the good predicted BBB permeabilities, physicochemical properties and low metabolic liabilities 
generate real potential for the compounds to be evaluated in in-vitro and in-vivo models for AD. 
The identification of this new class of compounds show promise for future research for 
developing a candidate for AD. 
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